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In spite of success of genome-wide association studies (GWAS) in identifying 
many common variants associated with complex diseases, the proportion of 
explained heritability in many cases remains small. Advances of sequencing 
technologies have enabled scientists to investigate rare variants, which hold the 
promise to explain the missing heritability and significantly improve our 
understanding of complex diseases for the purpose of designing the best treatment 
and prevention strategies.  
When performing a rare variants association analysis, researches face significant 
methodological challenges, since a single-variant strategy popular in GWA 
studies is underpowered when applied to rare variants due to the low number of 
minor alleles observed for each individual variant. Thus, analysis of multiple rare 
variants within a region was suggested as a strategy to improve statistical power. 
However, for region-based rare variants analysis, scientists encountered novel 
challenges, such as: (i) developing powerful methodologies for efficient 
combination of multiple rare variants; (ii) accounting for potential heterogeneous 
effect of rare variants within a region; and (iii) designing robust strategies with 
respect to the presence of multiple neutral rare variants.  
This thesis has focused on several areas within the rare variants analysis field 
where limited or no research had previously been done. The general aim of the 
thesis was comparison and development of novel rare variants statistical tests for 
analysis with dichotomous and quantitative traits. Study 1 was motivated by the 
observation that in spite of potential advantages of similarity-based approaches in 
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application to rare variants, no attempt has been made to compare similarity-based 
methods on rare variants association scenarios as well as to evaluate different 
ways to accommodate rare variants within the methods. Study 2 focused on 
developing a novel rare variants method that incorporates prior information, since 
limited research had been done within this area. Study 3 was motivated by the fact 
that in general, it is unknown in advance whether haplotypes or genotypes are 
more relevant for a disease when the underlying functional variants are unknown. 
Since genotype-based statistical methods are expected to perform better under 
genotype-based scenarios, whereas haplotype-based tests are likely to be more 
powerful when haplotypes are more relevant, it was necessary to develop a 
statistical method that possesses high power under both genotype- and haplotype-
based disease models. Study 4 filled in a gap of absence of a methodology that 
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Chapter 1 - Introduction 
Genome-wide association studies 
Genome-wide association study (GWAS) is an association study of common 
genetic variants (single base pair substitutions called single nucleotide 
polymorphisms or SNPs) across genome with a phenotype. It was previously 
estimated that there are around 10 million common SNPs (usually defined as 
SNPs with minor allele frequency (MAF) of at least 5%) in a human genome (The 
International HapMap project http://hapmap.ncbi.nlm.nih.gov). To perform 
GWAS, it is, however, not obligatory to genotype all common SNPs. Since 
variants situated in close proximity to each other are likely to be highly correlated 
(a phenomenon called linkage disequilibrium or LD), a small portion of common 
SNPs explain the overwhelming majority of genetic variation. Thus, in case-
control GWA studies, SNPs selected beforehand (also called tagSNPs) are 
genotyped in many individuals (often thousands) with and without a disease and 
tested for association with a disease status. In this case even though a true causal 
variant may not be genotyped in a study, it is likely that one of the SNPs which is 
in a high LD with that causal variant is present in a study and thus, can be 
detected. Usually, a single-variant approach, for example, Pearson chi-square test 
or Cochran-Armitage trend test, with the correction for multiple testing (e.g., 
Bonferroni correction) is used as a statistical framework in GWA studies. Given 
low cost of genotyping, GWA studies have become a routine way for successful 




Limitations of GWAS: the problem of missing heritability 
In spite of GWAS success, for many complex diseases and traits only a small 
proportion of heritability is explained by the discovered common variants.1; 2 For 
example, as it was noted by Cirulli et al3, despite the exceptionally large sample 
size in meta-analysis of GWA studies of type-2 diabetes (the authors cited a study 
of Zeggini et al4 which had the discovery panel of 10,128 samples and a 
replication panel of 53,975 samples), the discovered common variants explained 
only about 6% of total phenotypic variance attributable to genotype. Nirschhorn et 
al1 provided a table of estimates of the heritability explained by the variants 
discovered in GWAS for some of the diseases and traits as of August 2010. These 
estimates ranged from as high as 35% for Hemoglobin F levels to very low for 
autism. Since finding variants that explain the remaining phenotype variability 
will improve our understanding of the role of genetic factors in complex diseases 
and traits, it is necessary to investigate the sources of missing heritability. One of 
the possible explanations is that a large number of common variants with very 
low effect size affect disease susceptibility, but remain undetected due to 
insufficient power.5 Indeed, in this case hundreds of thousands of individuals are 
needed to ensure a good chance of detecting very low effect size common variants 
at a stringent genome-wide significance level. This proposition is supported by 
results from a very large scale GWA meta-analysis of BMI6 and height.7 Another 
potential explanation of the missing heritability is that numerous rare variants 
(defined as those with minor allele frequency below 1%), which are not present in 
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conventional GWA studies, could be the major contributors to the phenotypic 
variation. 
Rare variants association analysis 
Arguments for rare variants analysis 
Rapid development of next-generation sequencing technologies8 has enabled 
scientist to extend the realm of association studies to rare variants. With 
decreasing price of sequencing and development of novel sequencing platforms 
(referred to as second- and third-generation sequencing technologies)9 candidate 
regions, whole-exome or whole-genome association studies with large sample 
sizes may become as routine as GWA studies today. This suggests that novel rare 
variants associations across many phenotypes are likely to be discovered in a 
future. Indeed, there are strong arguments that support the hypothesis of 
involvement of rare variants in etiology of complex diseases. Some of those 
arguments are presented below: 
 Evolutionary theory predicts that fitness-reducing alleles should be rare. 
Indeed, if a disease is deleterious to fitness, variants that cause or are 
associated with that disease are likely to be under purifying selection, 
which may prevent them from reaching high MAF (minor allele 
frequency). However, a deleterious allele can still rise to MAF as high as 
1%5 under weak purifying selection due to genetic drift, recessive effect 
and repeated mutations. Lynch10 argued that the relaxed selection in 
modern humans may facilitate the accumulation of deleterious variants; 
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 Empirical data showed that deleterious variants are rare. Indeed, it was 
found that non-synonymous mutations are highly skewed towards low 
frequencies relatively to synonymous mutations.11 Given that as a class 
non-synonymous mutations are deleterious, this finding suggests that 
“selection keeps fitness-reducing alleles at a large proportion of genes at 
low frequency”;5  
 Numerous studies identified an association of rare variants with complex 
diseases or traits. Examples of phenotypes for which an involvement of 
rare variants was discovered include the following: asthma12, BMI13, 
colorectal adenomas14, dilated cardiomyopathy15, hypertriglyceridemia16, 
age-related macular degeneration17, multiple sclerosis18, prostate cancer19, 
rheumatoid arthritis20, schizoaffective spectrum diseases21, sterol 
absorption and plasma low-density lipoprotein levels22, and ulcerative 
colitis.23   
As can be seen, there is significant evidence supporting the hypothesis that rare 
variants are involved in etiology of complex diseases and traits.  
Challenges of rare variants association testing 
When performing an association analysis of rare variants, one faces significant 
methodological challenges. The problem stems from the fact that single-variant 
statistical approach which is popular in GWA studies has very low power to 
detect an association after correction for multiple testing due to small number of 




Figure 1: The sample size required to detect an association with a single rare variant as a 
function of relative risk and MAF. Extracted from Bansal et al.24 
The assumed statistical test is a conventional z-test for the difference in MAF between cases and 





Figure 2: The sample size required to detect an association with a single rare variant as a 
function of minor allele frequency ratio between cases and controls, and MAF. Extracted 
from Bansal et al.24 
The assumed statistical test is a conventional z-test for the difference in MAF between cases and 




This is clearly seen from Figures 1-224 which show the sample size required to 
detect an association with a single rare variant with 80% power at the genome-
wide type-1 error rate of 10−9 as a function of relative risk and frequency ratio 
between cases and controls respectively. The assumed test is a conventional z-test 
for the difference in MAF between cases and controls. As can be seen, the rarer 
the variant – the higher the sample size required to detect an association with the 
same power. In fact, the required sample size becomes extremely high for very 
rare variants (MAF=0.1%) and moderate effect sizes. This observation motivated 
the suggestion that rare variants analysis should be performed using a region-
based approach. Indeed, there are two major arguments for a region-based rare 
variants analysis. First of all, if there are multiple rare variants within a region that 
are associated with a phenotype, a region-based approach is likely to be more 
powerful than a single-variant approach, since a region-based test would combine 
an association signal from multiple variants. Secondly, the correction for multiple 
testing for a region-based approach is not as stringent as those for a single-variant 
approach. However, when performing a region-based rare variants analysis one 
encounters new challenges which are absent for a single-variant approaches, such 
as: 
 What are the methodologies for efficient and powerful combination of 
association signal from multiple rare variants? 
 How to account for a potential heterogeneous trait effect within a region: 
presence of both deleterious and protective rare variants? 
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 Which statistical approaches are robust to the presence of neutral variants 
within a region? 
Over the past years numerous researchers have attempted to overcome these 
challenges by developing novel statistical approaches. The next section will 
review the existing methodologies for a region-based rare variants analysis. 
Statistical methods for region-based rare variants analysis 
Next subsections will provide an overview of non-Bayesian region-based rare-
variants association tests for analysis of unrelated individuals with either a 
dichotomous phenotype or a quantitative trait. Let us assume we have sequenced 
a genomic region of interest in 𝑛 unrelated subjects and discovered 𝐿 rare 
variants. Also, let us introduce the following notations: 
 𝑌𝑖, 𝑖 = 1, … , 𝑛 – phenotype for an individual 𝑖, dichotomous or 
quantitative, unless specified; 
 𝑌 = (𝑌1, … , 𝑌𝑛) – a vector of phenotypes across samples; 
 𝐺𝑖𝑙, 𝑖 = 1, . . . , 𝑛, 𝑙 = 1, … , 𝐿 – a value of genotype for 𝑖th individual at the 
rare variant site 𝑙, coded as minor allele counts; 
 𝐺𝑙 = (𝐺1𝑙, … , 𝐺𝑛𝑙)
𝑇 – a vector of genotypes for the variant site 𝑙. 
Collapsing methods 
The first statistical test for an association analysis of rare variants, Cohort Allelic 
Sum Test (CAST), was proposed by Morgenthaler and Thilly25. The idea behind 
the CAST was to test an association of phenotype 𝑌 with a variable 𝐶 =
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(𝐶1, … , 𝐶𝑛)
𝑇 which is an indicator of presence of at least one rare minor allele 
within a region:  
𝐶𝑖 = 𝐼{𝐺𝑖1 > 0 𝑜𝑟 … 𝑜𝑟 𝐺𝑖𝐿 > 0}, (1) 
where 𝐼(𝐴) equals 1 when the event 𝐴 is true, and zero otherwise. The variable 𝐶 
is called a collapsed variable, or a super-locus. In general, the collapsed variable 
may be defined in another way, for example, as a number of rare minor alleles 
within a region of interest an individual carries:  




Zawistowski et al26 used the latter definition of collapsing to test an association of 
a super-locus with a dichotomous phenotype using Pearson 𝜒2 statistic. A super-
locus can also be considered within a regression framework, as follows: 
𝑌𝑖 = 𝑎 + 𝑏𝐶𝑖 + 𝑒𝑖, (3) 
for quantitative trait, or:  
𝑙𝑜𝑔𝑖𝑡 𝑃𝑟(𝑌𝑖 = 1) = 𝑎 + 𝑏𝐶𝑖 , (4) 
for dichotomous trait. Here 𝑎 and 𝑏 are the regression coefficients, 𝑒𝑖, 𝑖 = 1, … , 𝑛 
– error terms, 𝑙𝑜𝑔𝑖𝑡 is a logistic link function, Pr (𝑌𝑖 = 1) is a probability that the 
value of phenotype for an individual 𝑖 equals 1. The regression coefficient 𝑏 can 
be tested on deviation from zero using a score test or a likelihood ratio test.27  
Li and Leal28 extended the methodology of collapsing within a region by 
introducing Combined Multivariate and Collapsing (CMC) method. In the CMC 
approach rare variants are collapsed within groups defined, for example, by MAF 
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thresholds or other prior information. This set of collapsed variables is then tested 
for association with a phenotype using a multivariate statistical method. Madsen 
and Browning29 further extended the collapsing strategy by introducing Weighted 
Sum (WS) test. The key idea behind WS method is to calculate the weighted sum 
of minor alleles for each individual as follows: 




where 𝑤𝑙 is a weight for the 𝑙th variant, and then to test the variable 𝐶
𝑤on 
association with a phenotype using, for example, Wilcoxon rank sum test. The 
suggested weight for each rare variant was the inverse of the standard deviation of 
the number of minor allele counts observed in controls (assuming dichotomous 
trait). Thus, these weights increase with lower MAF. A rationale for upweighting 
rarer variants is the fact that strongly deleterious variants are likely to be under 
strong purifying selection and thus, have lower MAF.  
Methods that account for potential heterogeneous trait effect within a region 
All the rare variants methods described above have the following limitation: they 
implicitly assume that all rare variants influence a phenotype in the same direction 
(meaning, all causal variants are either entirely deleterious or entirely protective). 
To overcome this limitation, methods that account for potential presence of both 
deleterious and protective variants within a region have been developed. Most of 
these methods belong to one of the following two groups: adaptive collapsing and 
combination of single-variants test statistics. Adaptive collapsing group contains 
statistical tests which modify a collapsing algorithm to accommodate the 
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possibility of presence of both deleterious and protective variants within a region. 
Examples of adaptive collapsing tests are the following:  
 Lin and Tang30 assigned single variant regression coefficients shifted by a 
constant as weights to calculate the weighted sum variable 𝐶𝑤;  
 In a similar approach, Zhang et al31 used the transformed one-sided single-
variant p-values as weights in (5);  
 Analogously, Sha et al32 utilized single variant score test statistics 
multiplied by the weights from Madsen and Browning29 as 𝑤𝑙 in (5);  
 Han and Pan33 used the criteria of a negative sign and a magnitude (below 
some threshold) of single variant regression coefficients to change the 
coding of rare variants from 𝐺𝑙 to 2 − 𝐺𝑙, and then tested the super-locus 
(2) on association with a phenotype;  
 Dai et al34 applied a forward selection procedure to collapse variants. 
Namely, for each step a new variant is collapsed with a super-locus if that 
variant maximizes the correlation coefficient of the super-locus with a 
phenotype until no improvement in correlation is achievable. This 
procedure generates two super-loci: one for deleterious variants, and one 
for protective variants. The test statistic is the maximum of squared 
correlation coefficients between the super-loci and a phenotype.  
Since all of the approaches in this group use collapsing algorithm dependent on 
phenotype, for overwhelming majority of these methods the distribution of a test 
statistic under the null hypothesis is unknown. Thus, permutations should be used 
to estimate the significance level, which can be computationally expensive. 
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Methods that combine single variant test statistics usually sum up (or multiply) 
single variant statistics that are insensitive with respect to whether a variant is 
deleterious or protective. This group includes the following methods: C-alpha 
test35, a method by Ionita-Laza36, truncated product of p-values37, exponential 
combination of single variant chi-square statistics38, sum of squared scores from 
the following multiple regression model (SSU test):  
𝑌𝑖 = 𝑎 + ∑ 𝑏𝑙𝐺𝑖𝑙
𝐿
𝑙=1
+ 𝑒𝑖, (6) 
where 𝑏𝑙 , 𝑙 = 1, … , 𝐿 are regression coefficients.
39 It should be noted that C-alpha 
test has a known asymptotic distribution of test statistic under the null hypothesis 
when no covariates are included, and the test was shown to perform very well for 
many scenarios on simulated data sets.40 C-alpha test is a special case of one of 
the most popular rare variants methods, a Sequence Kernel Association Test 
(SKAT)41, discussed further as an example of similarity-based tests. 
Similarity-based tests 
Similarity-based methods are statistical approaches which use a multi-site 
genotype or phenotype similarity (or distance) measure between pairs of 
individuals. Many of these approaches are based on an assumption that haplotypes 
carrying the same causal mutation are likely to be more related than haplotypes 
without a causal mutation.42 To describe some of the similarity-based tests, let us 
first introduce multi-site genotype similarity measures. Denote as 𝐺𝑖
′ =
(𝐺𝑖1, … , 𝐺𝑖𝐿), 𝑖 = 1, … , 𝑛 a vector of genotypes across rare variants (or both rare 
and common variants in general) within a region for 𝑖th individual. A similarity 
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measure 𝑠 is a symmetric function which maps a pair of multi-site genotypes into 
a space of real numbers. The function 𝑠 is chosen such that the value of this 
function is higher if multi-site genotypes are more similar. Some of the tests 
described below do not have restrictions on the choice of 𝑠, whereas others 
require this function to be a kernel. Examples of popular similarity measures are 
the following:  
 (Weighted) Linear kernel 𝑠(𝐺𝑖
′, 𝐺𝑗
′) = ∑ 𝑤𝑙𝐺𝑖𝑙𝐺𝑗𝑙 ,   𝑖, 𝑗 = 1, … , 𝑛
𝐿
𝑙=1 , where 
𝑤𝑙, 𝑙 = 1, … , 𝐿 are fixed non-negative weights for the weighted similarity 
measure; 
 (Weighted) Quadratic kernel 𝑠(𝐺𝑖
′, 𝐺𝑗
′) = ∑ (1 + 𝑤𝑙𝐺𝑖𝑙𝐺𝑗𝑙)
2
,   𝑖, 𝑗 =𝐿𝑙=1
1, … , 𝑛; 
 (Weighted) IBS kernel 𝑠(𝐺𝑖
′, 𝐺𝑗
′) = ∑ 𝑤𝑙(2 − |𝐺𝑖𝑙 − 𝐺𝑗𝑙|),   𝑖, 𝑗 =
𝐿
𝑙=1
1, … , 𝑛; 
 (Weighted) Exponential kernel 𝑠(𝐺𝑖
′, 𝐺𝑗





} ,   𝑖, 𝑗 = 1, … , 𝑛 for normalized weights ∑ 𝑤𝑙 = 1
𝐿
𝑙=1 . 
Rare variants can be accommodated within the described similarity measures in 
two ways. First, one can use weights, for example, those proposed by Madsen and 
Browning29, to uplift rare variants. Another way is to collapse rare variants first, 
all together or within bins like in CMC method43, and then apply a similarity 
measure with uniform weights. Given a similarity measure 𝑠, one can calculate 
the genotype similarity for all pairs of individuals and define the following 











In the same way it is possible to introduce a phenotype similarity measure 𝑠𝑝, for 
example, a measure based on Euclidean distance 𝑠𝑝(𝑌𝑖, 𝑌𝑗) = −(𝑌𝑖 − 𝑌𝑗)
2
, or 
absolute difference 𝑠𝑝(𝑌𝑖, 𝑌𝑗) = −|𝑌𝑖 − 𝑌𝑗|.  
Alongside similarity functions, distance measures 𝑑 of multi-site genotypes or 𝑑𝑝 
of phenotype may be used in an association test. Examples of distance measures 
are the following: Euclidian distance 𝑑(𝐺𝑖, 𝐺𝑗) = ∑ (𝐺𝑖𝑙 − 𝐺𝑙𝑗)
2𝐿
𝑙=1 ; a sum of 
absolute differences 𝑑(𝐺𝑖, 𝐺𝑗) = ∑ |𝐺𝑖𝑙 − 𝐺𝑗𝑙|
𝐿
𝑙=1 . 
Association tests which use similarity or distance measures of multi-site genotype 
or phenotype include the following: U-test for dichotomous44 and quantitative45 
trait, Kernel-Based Association Test (KBAT)46, Mantel test47, Multivariate 
Distance Matrix Regression (MDMR) test48, and Sequence Kernel Association 
Test (SKAT).41 It should be noted that the SKAT test is one of the most popular 
and widely used association tests for a region-based rare variants analysis. SKAT 
is derived from the following semi-parametric regression model (for quantitative 
trait): 






where 𝑓 is an unknown function, 𝑋𝑖𝑘, 𝑘 = 1, … , 𝐾 are values of covariates such as 
age, gender, or genotype principal components to adjust for population 
stratification49 for 𝑖th individual, 𝑐𝑘, 𝑘 = 1, … , 𝐾 are the regression coefficients 
14 
 
for covariates. For a dichotomous trait a similar logistic model is used. SKAT test 
statistic is the following (in matrix notation): 
𝑆𝐾𝐴𝑇 = (𝑌 − ?̂?)
𝑇
𝑆(𝑌 − ?̂?), (9) 
where ?̂? is a vector of predicted phenotype values from the null regression model 
𝑌𝑖 = 𝑎 + ∑ 𝑐𝑘𝑋𝑖𝑘
𝐾
𝑘=1 , 𝑆 is a similarity matrix obtained using kernel similarity 
measure. The major advantages of SKAT over other methods are the following:  
theoretical distribution of the test statistics is known, it is easy to adjust for 
covariates within a test, and the test has been shown to perform very well on 
simulated data under many different association scenarios including when 
heterogeneous trait effect is present within a region.50 Lee et al51 proposed a 
modification of SKAT test (SKAT-O) which combines the original SKAT and a 
collapsing approach. The motivation for SKAT-O was that the new test would 
have an improved power under scenarios for which a collapsing method 
outperforms SKAT (e.g., when a large share of rare variants within a region are 
associated with a phenotype under homogeneous trait effect51).  
As can be seen, a number of similarity-based tests were proposed for an 
association analysis of rare variants. The major advantages of similarity-based 
tests are the following: (i) it is possible to test multiple DNA variations (deletions, 
insertions, copy number variations in addition to single base pair substitutions 
considered here) within the same test since a similarity measure can be chosen 
flexibly; (ii) an interaction within a region is potentially accounted for by using a 
multi-site genotype similarity measure. In addition, similarity-based tests may 
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perform very well compared with other rare variants methods. However, no 
comparison has been made between similarity-based tests on rare variants 
association scenarios, and no attempt has been made to evaluate whether 
collapsing or weighting is the best way to accommodate rare variants in the tests.  
Methods based on variable selection 
So far the methods described above have explicitly addressed two of the three 
challenges of region-based rare variants analysis provided in the previous section, 
namely, combination of association signal from multiple rare variants, and 
heterogeneous trait effect; however, the issue of neutral variants has not been 
discussed. This challenge is important because in general neutral variants add 
noise and thus, may significantly lower a power of a statistical test. This 
subsection describes methods that explicitly address the problem of neutral rare 
variants.  
Methodologies from this subsection can be divided into two groups: a penalized 
regression group and a variable selection group. Penalized regression group 
contains methods that use a penalized regression framework to shrink the number 
of rare variants within a region and thus, include only informative variants in a 
model. Let us consider a liner regression model for a quantitative trait 𝑌𝑖 = 𝑎 +
∑ 𝑏𝑙𝐺𝑖𝑙
𝐿
𝑙=1 + 𝑒𝑖 or a logistic model for a dichotomous trait 𝑙𝑜𝑔𝑖𝑡 𝑃𝑟(𝑌𝑖 = 1) =
𝑎 + ∑ 𝑏𝑙𝐺𝑖𝑙
𝐿
𝑙=1 . In a conventional regression model the estimates of regression 
coefficients are derived by maximizing a log-likelihood 𝐿(𝑎, 𝑏), where 𝑏 =
(𝑏1, … , 𝑏𝐿) is a vector of genotype regression coefficients. In a penalized 
regression model the estimates are derived from maximizing a penalized log-
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likelihood 𝐿(𝑎, 𝑏) − 𝑓(𝜆, 𝑏), where 𝑓(𝜆, 𝑏) is a penalty term, and 𝜆 is a parameter 
for a penalty function. There are many kinds of penalty terms investigated in the 
literature. Some of the most popular ones are LASSO penalty52 𝑓(𝜆, 𝑏) =
𝜆 ∑ |𝑏𝑙|
𝐿
𝑙=1 , ridge penalty
52 𝑓(𝜆, 𝑏) = 𝜆 ∑ 𝑏𝑙
2𝐿
𝑙=1 , elastic penalty
53 𝑓(𝜆, 𝑏) =
𝜆1 ∑ |𝑏𝑙|
𝐿
𝑙=1 + 𝜆2 ∑ 𝑏𝑙
2𝐿
𝑙=1 , and others.
54; 55  
Methodologies from a variable selection group attempt to select an informative 
set of rare variants using some heuristic algorithm. Price et al56 developed the VT 
test which utilizes the following steps: (i) collapse rare variants with MAF below 
a frequency threshold 𝑡, namely, 𝐶(𝑡) = ∑ 𝐺𝑙𝐼{𝑀𝐴𝐹𝑙 < 𝑡}
𝐿
𝑙=1 ; (ii) then calculate a 
standardized test statistic 𝑠(𝑡) (e.g. z-score statistic for a regression model) for an 
association of 𝐶(𝑡) with a phenotype, and (iii) use max
𝑡
𝑠(𝑡) as a final test 
statistic. The rationale behind this approach is the assumption that variants below 
some unknown frequency threshold are more likely to be functional than variants 
with MAF over that threshold. Fang et al57 suggested a modification of the VT  
test in which variants are ordered not by MAF, but by the ratio of MAF in cases 
and controls. Bhatia et al58 and Ionita-Laza et al59 suggested the maximum of test 
statistics calculated over a sliding window of fixed and variable size respectively. 
To sum up, numerous methodologies (penalized regression models, and 
approaches based on heuristic variant selection) have been proposed to explicitly 
address the issue of neutral variants within a region.  
Statistical tests that incorporate prior information 
All the statistical methods mentioned above do not utilize any information other 
17 
 
than genotype and phenotype. Given the formidable challenges researchers face 
when analyzing rare variants with moderate sample size, there is a motivation to 
use any available external information with the purpose of increasing likelihood 
to identify true association. With the development of technology and biological 
knowledge, vast amount of prior information has become publicly available, such 
as those from the National Centre for Biotechnology (NCBI) variation database60, 
variant annotation (SNPNexus61), conserved region information from UCSC 
Genome Browser62, predictions of degree of deleteriousness for non-synonymous 
variants (SIFT63, PolyPhen64) etc. As a result, some of the statistical approaches 
described below incorporate prior knowledge in an association test. 
In general, quantitative information such as PolyPhen or SIFT scores for non-
synonymous variants, or sequencing quality scores may be used as weights in any 
approach which allows weighting of variants. If rare variants weights are 
correlated with an indicator of being associated, a test is likely to gain power over 
methods that do not utilize such information. Specifically, Price et al,56 alongside 
their VT approach, suggested that instead of collapsing variants below a variable 
threshold one can use a sum of minor alleles weighted by PolyPhen scores. In a 
similar approach Asimit et al65 proposed using a sum of minor alleles weighted by 
sequencing quality scores, which equal to – log10(𝑃𝑙), 𝑙 = 1, … , 𝐿, where 𝑃𝑙 is the 
probability of erroneous variant call for 𝑙th variant. Another approach is to cluster 
rare variants into bins based on prior information, and then apply a statistical test 
to the set of collapsed within bins rare variants. An example of such an approach 
is those by Moore et al66, which uses numerous publicly available databases to bin 
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rare variants. Yet another approach is to use information obtained from population 
genetics simulations. King et al67 considered an evolutionary framework in which 
an estimates of fitness effect of each rare variant and its error are derived from 
simulations. 
Incorporation of prior information into a statistical strategy has a large potential to 
improve power of rare variants association studies. Given a limited research in 
this field, it is, therefore, necessary to develop statistical methods that would be 
able to utilize prior information. 
Rare haplotype tests 
This group of rare variants methods contains approaches that test rare haplotypes 
on association with a phenotype. There are several possible reasons why a 
haplotype-based association test may be more powerful than a genotype-based 
one. First of all, if true causal variants are not present in a study, haplotypes may 
tag them much better than single variants since a haplotype is a set of alleles on a 
chromosome which tend to be transmitted together. Secondly, haplotype-based 
methods are likely to be more powerful when there is an interaction of variants 
within a region. Given that in most association studies only genotypes are 
available, one faces a problem of haplotype inference. Numerous statistical 
phasing algorithms have been developed to infer haplotypes in GWAS data sets68-
70; however, the accuracy of statistical inference may be low for rare haplotypes. 
Novel haplotype assembly algorithms71-73 which utilize sequencing reads hold the 
promise for high-quality haplotype reconstruction in sequencing studies. 
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The proposed rare haplotype tests include the weighted haplotype method74, 
generalized haplotype liner model75 and haplotype kernel association test76. In 
general, it is unknown in advance whether haplotypes or genotypes are more 
relevant for a disease. Genotype-based statistical methods are expected to perform 
better under genotype-based scenarios; whereas haplotype-based tests are likely to 
be more powerful when haplotypes are more relevant. Therefore, it is necessary to 
develop a statistical method that possesses high power under both genotype- and 
haplotype-based disease models. 
Other region-based rare variants methods 
A number of proposed statistical methods have not been mentioned so far since 
they do not seem to fit into the classification considered above. They include the 
following methods: a likelihood ratio test using an expectation maximization 
algorithm77, mixed-effect regression model with a fixed effect collapsed rare 
variants78, Kernel-Based Adaptive Cluster (KBAC)79, private variants test22, Rare 
Variant Weighted Aggregate Statistic (RWAS)80, spatial approach81 etc. The 
summary of region-based rare variants statistical methods is presented in  
Appendix to Chapter 1. 
Region-based rare variants meta-analysis 
Meta-analysis is an association analysis which combines multiple studies with the 
purpose of increasing sample size and thus, improving a chance of identifying 
susceptibility regions that were not identified in any of the included studies. Meta-
analysis has been successfully applied to GWAS data sets and helped to identify 
hundreds of novel associations.4; 82 With sequencing studies becoming more 
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common, rare variants meta-analysis holds a promise to identify novel regions 
that harbor rare variants with moderate effect size. In spite of enlarged sample 
size, single variant approach to meta-analysis is still underpowered at the stringent 
genome-wide significance level. Thus, region-based meta-analysis methods 
should be considered.  
Rare variants meta-analysis approaches can be divided into two groups: p-value-
based meta-analysis, and summary statistics combination approaches. The first 
group includes methods that combine region-based single study p-values. In 
general, those p-values can be obtained using any region-based rare variants 
statistical test. So, given the single study p-values 𝑝1, … , 𝑝𝑁, where 𝑁 is a number 
of studies in a meta-analysis, the following approaches can be applied: 
 Conventional Fisher p-value combination: −2 ∑ log (𝑝𝑛)
𝑁
𝑛=1  which has a 
𝜒2𝑁
2  distribution under the null hypothesis; 
 Stouffer method83: ∑ Φ−1(1 − 𝑝𝑛
𝑁
𝑛=1 )/√𝑁, where Φ
−1 is an inverse 
standard normal transformation.  The statistic has a standard normal 
distribution under the null hypothesis. If the sample sizes of studies in 
meta-analysis are not equal, it is possible to weight the terms in a sum by 
square root of sample size to emphasize that more evidence should come 
from large sample studies if the alternative hypothesis holds; 
 Truncated product of p-values84: ∏ 𝑝𝑛
𝐼{𝑝𝑛<𝑡}𝑁
𝑛=1 , where 𝑡 is a truncation 
point, commonly assigned to be 0.05; 
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 Rank-truncated product of p-values85: ∏ 𝑝(𝑛)
𝐾
𝑛=1 , where 1 ≤ 𝐾 < 𝑁 is a 
fixed truncation rank, and 𝑝(1) ≤ 𝑝(2) ≤ ⋯ ≤ 𝑝(𝑁) is an ordered sequence 
of p-values, from the lowest to the highest; 
 Adaptive rank-truncated product of p-values.86 Let 𝑠(𝐾) be a p-value from 




Several methods that combine summary statistics across studies in meta-analysis 
have also been proposed in a literature, such as MetaSKAT tests87 and methods by 
Hu et al.88 
Given that sequencing association studies are conducted across populations 
worldwide, trans-ethnic meta-analysis has a highest potential to improve a power 
to identify true rare variant associations. However, there are significant challenges 
for trans-ethnic rare variants meta-analysis such as allelic heterogeneity (different 
sets of variants bear an association signal across different ethnic groups) and 
effect size heterogeneity (different strength of association across ethnic groups 
due to, for example, environmental or lifestyle factors). Therefore, it is important 
to develop a powerful meta-analysis method that would address both allelic and 
effect size heterogeneity issues. 
Research objectives 
As can be seen from the literature review above there are several areas within the 
field of statistical genetics where a limited or no research has been done so far. 
The research gaps for this thesis are summarized below: 
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 No attempt has been made to evaluate the relative performance of 
similarity-based tests applied with different ways to accommodate rare 
variants (collapsing or weighting) on association scenarios with causal 
rare variants; 
 Given a large potential of prior information to improve a statistical power 
of rare variants association analysis, it is important to develop novel 
methodologies that effectively incorporate prior knowledge. So far, 
limited research has been done in this area of statistical genetics;  
 Since it is unknown priori whether haplotypes of genotypes are more 
relevant for an association of a genomic region with a disease, it is 
important to develop methods that possess high power under both 
association scenarios;  
 Both allelic and effect size heterogeneity are the significant challenges for 
trans-ethnic rare variants meta-analysis. Limited research has been done so 
far to address these issues.  
The major aim of the thesis was to address the research gaps summarized above. 
The specific aims of the research were to: 
 compare similarity-based tests applied with different ways to 
accommodate rare variants within a test on rare variants association 
scenarios (Study 1); 
 develop a powerful region-based rare variants association test that 
incorporates prior information (Study 2); 
23 
 
 develop a powerful statistical approach for both genotype- and haplotype-
based association scenarios (Study 3); 
 develop a rare variants meta-analytic framework that would address the 
issues of allelic and effect size heterogeneity in trans-ethnic rare variants 
meta-analysis (Study 4).  
The results of this thesis could help researchers to discover novel associations of 
rare variants with diseases and complex traits by providing powerful statistical 
tools for rare variants association studies. Also, the investigation of the 
performance of rare variants methods on different association scenarios could 
prove to be useful for choosing the right statistical tools for rare variants analysis.  
The scope of the thesis includes only association studies with unrelated 
individuals because it is one of the most common designs for an association study. 
Also, only quantitative or dichotomous phenotypes were considered since these 
types of phenotype are the most commonly encountered ones in association 









Chapter 2 – Comparison of similarity-based tests and pooling 
strategies for rare variants 
Background 
Although genome-wide association studies (GWAS) have identified many 
common single nucleotide polymorphisms (SNPs) associated with common 
diseases (http://www.genome.gov/gwastudies),  these common variants explain 
only a small fraction of the phenotypic variance attributable to genetic factors.1; 2 
Recently, the scientific community has devoted much attention to the analysis of 
rare variants with the purpose of finding missing heritability. Indeed, there is 
growing evidence that rare variants are associated with some complex traits.15; 18; 
21; 89 Therefore, research in the area of rare variants has a high potential to 
discover unknown associations of genomic regions with complex diseases. As a 
result, numerous methodologies have been developed to test an association of 
multiple rare variants with a phenotype.24  
Measures of genotype similarity have been the basis of some of the proposed 
statistical tests. The idea of similarity-based tests is to consider the relationship 
between genotypic and phenotypic similarities (similarity here roughly refers to a 
measure of closeness of two genotypes or phenotypes). Similarity-based tests are 
motivated by the fact that haplotypes carrying the same causal mutation are more 
similar compared with those without causal mutations; so, case haplotypes are 
expected to share longer stretches of DNA identical by descent.42 One of the 
major advantages of similarity-based tests is the ability to accommodate multiple 
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types of DNA variations (SNPs, insertions and deletions, CNVs) observed within 
a region, given a flexibility in the choice of similarity measures between two 
sequences.90 Another issue that similarity-based tests address is an interaction of 
different variants within a region, which is potentially accounted for by 
considering multi-site similarity measures.91 For unrelated individuals similarity 
measures have been incorporated within a framework of single SNP analysis of 
variance,92 multiple regression,93 U-statistic44 and distance-based regression.91 
Methods based on genotype similarity include the following: sequence kernel 
association test (SKAT),41 kernel-based association test (KBAT),46 multivariate 
distance matrix regression test (MDMR),48 and aggregate U-test.45 So far no 
attempts have been made to evaluate the performance of similarity-based tests on 
rare variants association scenarios when common variants are included in or 
excluded from the analysis. Even though many non-causal common SNPs are 
removed by considering only rare variants, it is unclear if consideration of fewer 
variants would be sufficient to compensate for the loss of association signal from 
common SNPs. Additionally, statistical tests may utilize different pooling 
strategies for rare variants, e.g., weighting or collapsing. Given the choice, it is 
unclear which pooling strategy is the best to be applied with similarity-based 
tests.  
We compared the performance of four similarity-based tests (SKAT, KBAT, 
MDMR and a modified U-test44) applied with two popular rare variants pooling 
strategies (weighting and collapsing). The comparison was performed using 
population-genetics simulations under four different disease models and the 
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GAW17 sequencing data set. The results highlighted that under the presence of 
strong rare variants association signal and moderate association of common 
variants, weighting may be a much better strategy than collapsing, whereas 
collapsing tended to outperform weighting when common variants possessed 
strong effect. Moreover, we discovered that the magnitude of the difference in 
power among similarity-based methods when applied with weighting and 
collapsing strategies may be very high, sometimes reaching over 50%. Also, 
under strong effect size of rare variants when common variants were excluded 
from analysis, we observed better performance of collapsing strategy and lower 
power of weighting pooling strategy. Finally, when the appropriate pooling 
strategy was applied, both SKAT and KBAT showed consistently high power 
among all the four similarity-based tests considered here.  
Methods 
Similarity-based tests 
Assume that an association study involves 𝑁 individuals (𝑁𝐴 cases and 𝑁𝑈 
controls), and within a genomic region 𝐿 SNPs (both common and rare) were 
called. Let us denote the genotype matrix 𝐺 = {𝑔𝑛𝑙, 𝑛 = 1, … , 𝑁  𝑙 = 1, … , 𝐿} 
coded as minor allele counts, and the phenotype vector 𝑌 = {𝑦𝑛, 𝑛 = 1, … , 𝑁} 
with the elements valued 1 for cases and −1 for controls (except when otherwise 
specified). The 𝑁 × 𝑁 similarity matrix is defined as 𝐾 = {𝑠(𝑔𝑛, 𝑔𝑚)}𝑛,𝑚=1
𝑁 , 
where 𝑔𝑛 = {𝑔1𝑛, … , 𝑔𝐿𝑛}, 𝑛 = 1, … , 𝑁 is a multi-site vector of genotype for 𝑛th 
individual, and 𝑠(𝑥, 𝑦) is a similarity function. There is a variety of examples of 
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similarity functions published in statistical genetics literature (for examples, see 
Wu et al,41 Wessel and Shork,91 and Mukhopadhyay et al92). However, it is 
desirable for the similarity matrix 𝐾 to be symmetric positive semi-definite as this 
is “the key to its use in many statistical analyses”.94 Thus, we consider only those 
similarity measures that result in a positive definite similarity matrix. Examples of 
such similarity measures are the weighted linear kernel 𝑠(𝑔𝑛, 𝑔𝑚) =
∑ 𝑤𝑙𝑔𝑛𝑙𝑔𝑚𝑙
𝐿
𝑙=1  for some fixed weights 𝑤𝑙 , 𝑙 = 1, … , 𝐿, the weighted quadratic 
kernel 𝑠(𝑔𝑛, 𝑔𝑚) = (1 + ∑ 𝑤𝑙𝑔𝑛𝑙𝑔𝑚𝑙
𝐿
𝑙=1 )
2, and the weighted IBS kernel 
𝑠(𝑔𝑛, 𝑔𝑚) = ∑ 𝑤𝑙(2 − |𝑔𝑛𝑙 − 𝑔𝑚𝑙|)
𝐿
𝑙=1 . For our analysis, a popular exponential 
similarity measure95 was used: 





The choice of similarity was motivated by the need to analyze quantitative 
genotype obtained as a result of population stratification adjustment (see the 
“Results” section). As the exponential similarity is a function of the Euclidean 
distance between two multi-site genotypes, we consider this similarity to be more 
appropriate compared with, for example, another popular similarity measure 
identity-by-state44, which was designed to be applied to genotype codes. 
Weighting and collapsing 
We considered two major ways of rare variants pooling: weighting and 
collapsing. Let us denote SNP weights as 𝑤 = {𝑤𝑙, 𝑙 = 1, … , 𝐿}. In general, they 
may be derived from observed minor allele frequency (MAF) or prior 
information. Here we adopted the weights proposed by Wu et al41 𝑤𝑙 =
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𝐵𝑒𝑡𝑎(𝑚𝑎𝑓𝑙;  1, 25)
2, where 𝑚𝑎𝑓𝑙  is MAF of 𝑙th SNP, 𝐵𝑒𝑡𝑎(𝑎; 𝑏, 𝑐) is the beta 
density distribution function with parameters 𝑏 and 𝑐 evaluated at point 𝑎. The 
weight function monotonically increases as MAF decreases while, as noted by the 
authors, “putting decent nonzero weights for variants with MAF 1%–5%”. As 
noted by Wu et al41, setting 0 ≤ 𝑏 ≤ 1 and 𝑐 ≥ 1 allows for an increase in 
weights of rare variants and a decrease in weights of common variants. Thus, any 
values of parameters 𝑏 and 𝑐 from the specified range are acceptable. For the 
three tests (SKAT, MDMR and U-test), the weights were incorporated via the 
calculation of similarity matrix. Specifically, the weights incorporating similarity 
function 𝑠𝑤 for the similarity matrix 𝐾𝑤 is as follows: 





𝑙=1 }. (11) 
For the KBAT test statistic the weights were incorporated differently (for details, 
see the “Kernel-based association test (KBAT)” subsection below) as the test does 
not use the multi-site genotype similarity.  
Collapsing of rare variants was performed as described in Thalamuthu et al,46 
namely, by defining a super-locus 𝑔𝑛(𝐿+1), 𝑛 = 1, … , 𝑁 as follows: 
𝑔𝑛(𝐿+1) = 𝑚𝑖𝑛{2, ∑ (𝑔𝑛𝑙)𝑙:𝑚𝑎𝑓𝑙≤0.01 }. (12) 
In general this type of collapsing preserves more information than an indicator of 
at least one rare variant being present, as suggested by Li and Leal.28 The 
collapsed genotype is treated as a new SNP 𝑔𝑛(𝐿+1), 𝑛 = 1, … , 𝑁, and a similarity 
matrix is constructed using common variants and this super-locus.  
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Multivariate distance matrix regression (MDMR) 
Let us denote 𝑁 × 𝑁 identity matrix as 𝐼𝑁 and a vector of 1 of size 𝑁 as 1𝑁. 
Following Wessel and Schork91, the test statistic is calculated according to the 
algorithm: 
 Phenotype projection matrix 𝐻 = 𝑌(𝑌𝑇𝑌)−1𝑌𝑇, where upper 𝑇 denotes 
transposition; 
 Dissimilarity matrix 𝐷 = {𝑑𝑖𝑗}𝑖,𝑗=1
𝑁
= 1𝑁1𝑁
𝑇 − 𝐾, where 𝐾 is a similarity 
matrix defined above; 
 Gover’s centered matrix 𝐺 = (𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁)𝐴(𝐼𝑁 − 1𝑁1𝑁









 The test statistic 𝑀𝐷𝑀𝑅 = 𝑡𝑟(𝐻𝐺𝐻)/𝑡𝑟((𝐼𝑁 − 𝐻)𝐺(𝐼𝑁 − 𝐻)), where 𝑡𝑟 
is matrix trace. 
Large values of the test statistic indicate deviation from the null hypothesis of no 
association of genotype with phenotype. 
Sequence kernel association test (SKAT) 
For this test the phenotype vector 𝑌 = {𝑦𝑛, 𝑛 = 1, . . , 𝑁} is coded as 1 for cases 
and 0 for controls. The mean phenotype vector is defined as ?̅? = 𝑁𝐴1𝑁/𝑁. 
Following Wu et al41, the test statistic is 𝑆𝐾𝐴𝑇 = (𝑌 − ?̅?)𝑇𝐾(𝑌 − ?̅?)/2. Under 
the null hypothesis the 𝑆𝐾𝐴𝑇 test statistic is asymptotically distributed as the 
weighted sum of chi-squared random variables with one degree of freedom. Thus, 
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the significance level can be assessed theoretically. Permutations can also be used 
to estimate a p-value empirically. 
U-test 
The average similarity scores between pairs of cases 𝑈1 and controls 𝑈0 are 
defined as follows: 












where 𝐾𝑛𝑚, 𝑛, 𝑚 = 1, … , 𝑁 are the elements of the similarity matrix 𝐾 (𝐾 =
{𝐾𝑛𝑚}𝑛,𝑚=1
𝑁 ). The U-test statistic is 𝑈 = (𝑈1 − 𝑈0)
2. Note that Shaid et al44 
considered the weighted sum of single SNP U-test statistics, where weights were 
derived from the asymptotic variance-covariance matrix of the U statistics vector. 
However, for the purpose of comparison of weighting and collapsing rare variants 
pooling strategies the statistic was modified as described above. The modified test 
statistic 𝑈 is similar to the single SNP U-test statistic proposed by Shaid et al44, 
but it incorporates the similarity information across multiple variants within a 
region. Permutations need to be applied to assess p-value. 
Kernel-based association test (KBAT) 
Let us denote 𝐾𝑙 = {(𝐾𝑙)𝑛𝑚}𝑛,𝑚=1
𝑁  as a single SNP similarity matrix for 𝑙th 
variant. Similar to the notations of the previous subsection, let us denote as 𝑈𝑙1 
and 𝑈𝑙0 the average similarity scores for pairs of cases and controls, respectively, 
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calculated from 𝐾𝑙, and let 𝑈𝑙 = (𝑈𝑙1 + 𝑈𝑙0)/2. Following Mukhopadhyay et al
92, 
consider within-group and between-group sum of squares:  



















where the two groups are case-case and control-control pairs. The test statistic is 
𝐾𝐵𝐴𝑇 = ∑ 𝐵𝑆𝑆𝑙
𝐿
𝑙=1 / ∑ 𝑊𝑆𝑆𝑙
𝐿
𝑙=1 . Since the test does not utilize the multi-site 
similarity matrix (only single SNP matrices 𝐾𝑙), the weighted test statistic 
𝐾𝐵𝐴𝑇𝑤 = ∑ 𝑤𝑙𝐵𝑆𝑆𝑙
𝐿
𝑙=1 / ∑ 𝑤𝑙𝑊𝑆𝑆𝑙
𝐿
𝑙=1  is used here. Large value of 𝐾𝐵𝐴𝑇 
statistic indicates deviation from the null hypothesis. Permutations are used to 
assess a p-value. 
Population genetics simulations 
Genotype simulation was based on a population genetics history of European 
population for the exonic regions of ANGPTL4 gene (seven exonic regions of 
total length 1895 bps). To simulate genotypic variants forward population 
genetics simulator SFS_CODE (http://sfscode.sourceforge.net) was used with a 
program provided by King et al.67 The program simultaneously implements the 
demographic history of African-Americans, Europeans and Asians with the 
demographic and distribution fitness effect parameters from Boyko et al96 and 
Gutenkunst et al.97 The assumed mutation rate was 1.8/108 per nucleotide per 
generation, and the local recombination rate was 4 cM/mb with no recombination 
hotspots. Using the program we generated 1000 haplotype pools each containing 
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20,000 sampled “individuals” (40,000 chromosomes) from European population. 
The same haplotype pools were used for simulations of all phenotype models. 
One haplotype pool was used for one data replicate. 
To generate a data replicate we sampled a pair of haplotypes randomly from a 
haplotype pool and took the corresponding alleles from each position to get the 
marker genotypes. The phenotype was assigned based on multi-site genotype 
using a linear logistic model whose parameters depended on phenotype model. 
For our simulations four phenotype models were implemented: “Risk Rare”– only 
risk-contributing rare variants were present within a region; “Risk Both”– both 
rare and common variants were causal with rare ones having larger impact; “Risk 
Common” – both rare and common variants were causal with common ones 
having larger impact; and “Mixed Rare” – both risk-contributing and protective 
rare variants were present. Causal SNPs were sampled randomly according to a 
scenario described in Table 1. For example, for “Risk Rare” scenario roughly 
50% of the rare variants found within a haplotype pool were assigned to be 
causal. To describe the phenotype generation procedure let us denote as 
{𝑔1, … , 𝑔𝑐} the genotype of an “individual” at variants chosen to be causal, 
{𝑔𝑐+1, … , 𝑔𝐿} – the genotype at other SNPs, and {𝑏1, … , 𝑏𝑐} – the assigned odds 
ratio of causal variants (vary depending on scenario, see Table 1). The probability 




) = log (
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Causal variants choice description 
OR for each causal 
minor allele 
Rare Common Rare Common 
Risk Rare 50% of r. v. in a pool - 4 - 
Risk Both 50% of r. v. in a pool 1 SNP 3 1.2 
Risk Common 50% of r. v. in a pool 1 SNP 1.5 2 
Mixed Rare 
Risk-contributing: 
25% of r. v. in a pool; 
Protective:  
25% of r. v. in a pool; 
- 4 or 1/4 - 
Table 1: Summary of disease models for the four scenarios in population genetics simulation. 
Extracted from Zakharov et al.98 
Rare variants (r.v. in the Table) are defined as SNPs with observed MAF ≤ 1% in a haplotype 




Rare Common Rare Common 
Risk Rare 17.3/- 1.3/- 13.1 5.9 
Risk Both 16.3/- 1.9/- 13.2 4.9 
Risk Common 13.9/- 1.3/- 13.1 4.9 
Mixed Rare 8.9/5.2 0.6/0.03 13.2 5.9 
Table 2: The average number of causal and non-causal variants in data replicates by 
frequency category: rare and common. Adapted from Zakharov et al.98 







Penetrance of wild type genotype was assumed to be 1% for all scenarios. The 
procedure of haplotype sampling and phenotype assigning proceeded until there 
were 500 cases and 500 controls. The average number of SNPs across data 
replicates for each phenotype model is presented in Table 2.  
Results 
Population genetic simulations 
For each test 1000 permutations were performed to assess significance of 
association. To make sure the empirical type-1 error was controlled, we ran the 
analysis of simulated data under the null model. As can be seen from Table 3, the 
type-1 error was well controlled by using permutations. It is noticeable that for 
“Risk Rare” scenario when weighting pooling strategy was applied and for “Risk 
Common” scenario the estimates of type-1 error were below 0.05. This suggests 
that in these cases the methods showed slightly conservative behavior.  
Scenario 
Collapsing/Weighting 
MDMR SKAT KBAT U-test 
Risk Rare 0.055/0.042 0.055/0.039 0.042/0.04 0.056/0.049 
Risk Both 0.05/0.052 0.051/0.039 0.046/0.04 0.044/0.054 
Risk Common 0.039/0.048 0.038/0.046 0.048/0.046 0.044/0.038 
Mixed Rare 0.053/0.046 0.045/0.055 0.055/0.051 0.051/0.044 
Table 3: Empirical type-1 error rate for different disease scenarios, rare variants pooling 
strategies and statistical tests in population genetics simulations. Adapted from Zakharov et 
al.98 
For each test type-1 error for collapsing/weighting rare variants pooling strategy is shown. The 




The two-sided 99% confidence interval for the type-1 error estimate is 
approximately 0.033–0.067. This can be derived from the normal approximation, 
given that the estimate of type-1 error rate is distributed as an observed 
probability of success for a binomial random variable with a success probability 
of 0.05 under no inflation of type-1 error and the sample size of 1000, which is 
the number of data replicates. As can be seen, the empirical type-1 error estimates 
for population genetics simulations were within the 99% confidence interval. 
Figure 3 shows the power of the four tests with collapsing and weighting pooling 
strategies under different association scenarios. As can be seen from Panel 1 
(“Risk Rare” scenario), the powers of the tests were in the following order: for 
collapsing MDMR performed no worse than SKAT but no better than U-test, 
which in turn had lower power compared to KBAT; for weighting MDMR 
performed worse than KBAT, and KBAT was no more powerful than SKAT, 
whereas U-test was the most powerful among all the four tests considered. Also, 
weighting increased the power of all the tests, except for MDMR. The same 
situation was observed when a weak association signal from common variants 
was introduced together with weaker signal from rare variants (“Risk Both” 
scenario in Panel 2 of Figure 3). The performance of the tests when rare variants 
had lower effect compared with common variants (“Risk Common” scenario) is 
presented in Panel 3 of Figure 3. As can be seen, the pattern is different from 
those observed for the previous two scenarios. For all the tests, the collapsing 
strategy performed better than weighting. These results suggest that weighting 



























Figure 3: Power as a function of significance level for the four similarity-based tests and two 
rare variants pooling strategies. Extracted from Zakharov et al.98 
Panel 1: “Risk Rare” Scenario; Panel 2: “Risk Both” Scenario; Panel 3: “Risk Common” Scenario; 
Panel 4: “Mixed Rare” Scenario.  
 
when common variants explain a significant portion of phenotype variability, 
collapsing is more advantageous since weighting undermines the signal from 
common variants. Finally, we investigated the performance of the tests in the 
“Mixed Rare” scenario which incorporated both risk and protective variants 
within a region (Figure 3, Panel 4). As expected, collapsing underperformed 
weighting pooling strategy, since collapsing risk and protective variants 
annihilated an association signal. Overall, the simulation results highlighted 
consistently high power of KBAT and SKAT when the appropriate rare variants 
pooling strategy was applied (namely, collapsing for “Risk Common” scenario, 
and weighting for other scenarios). Although these two tests had slightly lower 
power compared to the U-test for “Risk Rare” and “Risk Both” scenarios, they 
had much higher power for the other two scenarios.  
Also, we calculated the maximum absolute power difference between weighting  
and collapsing strategies over the significance level for each test and phenotype 
scenario. As can be seen from Table 4, the maximum absolute power difference 
was substantial and ranged from as low as 10% to as high as 55%. The average 
maximum absolute power difference for the considered tests across the phenotype 
models were 39.8%, 43.9%, 25.8% and 31.8% for MDMR, SKAT, KBAT and U-
test respectively. This result shows the extreme importance of choosing the right 
rare variants pooling strategy for different disease models.  
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Scenario MDMR SKAT KBAT U-Test 
Risk Rare 0.466 0.472 0.157 0.511 
Risk Both 0.395 0.29 0.094 0.379 
Risk Common 0.551 0.479 0.388 0.235 
Mixed Rare 0.18 0.516 0.393 0.148 
Table 4: The maximum absolute difference in power (over the type-1 error rate) between 
weighting and collapsing pooling strategies for different tests and phenotype scenarios in 
population genetics simulations. Extracted from Zakharov et al.98 
Additionally, we analyzed the simulated data using another popular similarity 
measure: identity-by-state.91 The results were similar to those obtained for the 
exponential similarity (Figure 4). We also analyzed the simulated data with all 
common variants (defined as those with MAF > 1%) excluded from analysis 
(Figure 5). In this case association tests with collapsing pooling strategy were 
performed only on a collapsed super-locus. In contrast to the previous results for 
“Risk Rare” and “Risk Both” scenarios collapsing performed better and weighting 
performed worse. For the collapsing strategy the reduction in the number of SNPs 
was beneficial despite the loss of association signal from the excluded common 
SNPs. However, for the weighting pooling strategy the loss of some of the causal 
variants with MAF above 1% lowered the statistical power of the tests. Hence, the 
results suggest that under strong rare variants effect size in one direction one 
should prefer collapsing to weighting when common variants are excluded from 
an association test. For the “Risk Common” scenario the power of all the tests and 
all pooling strategies was lower, as the strong association signal from common 
variants was removed. For the “Mixed Rare” model the results were similar to 



























Figure 4: Power as a function of significance level for the four similarity-based tests with IBS 
kernels and two rare variants pooling strategies. Extracted from Zakharov et al.98 
Panel 1: “Risk Rare” Scenario; Panel 2: “Risk Both” Scenario; Panel 3: “Risk Common” Scenario; 
Panel 4: “Mixed Rare” Scenario.  
 
GAW17 data set 
GAW17 is a large scale exome sequencing data set with genotypes from the 1000 
Genomes Project (http://www.1000genomes.org). The data set consists of 697 
unrelated individuals from six populations (Centre d'Etude du Polymorphisme 
Humain (CEPH) samples, Tuscan, Chinese, Japanese, Yoruba and Luhya). The 
complex phenotype model incorporates environmental covariates (age, gender 
and smoking status) and both common and rare causal SNPs from genes in 
particular pathways. Totally 200 replicates of several quantitative traits and case-
control status were simulated. A more detailed description of the simulations can 
be found in Almasy et al.99  
We performed an association analysis of causal genes that affect two quantitative 
traits Q1 and Q2, and a dichotomous trait 𝐷. Adjustment for covariates was done 
in a similar way as in Jiang et al.100 Let 𝐺 be the genotype matrix, Qj, 𝑗 = 1,2 are 
vectors of two quantitative traits, 𝐸𝑖 , 𝑖 = 1,2,3, are vectors of covariates (age, 
gender and smoking status, respectively), and 𝑅 is the matrix of ten principal 
components of genotype matrix obtained using the software Eigenstrat.49 The 
corrected genotype, phenotypes and covariates are ?̌? = 𝐺 − 𝑅𝑅𝑇𝐺, 𝑄?̃? = 𝑄𝑗 −
𝑅𝑅𝑇𝑄𝑗, 𝑗 = 1,2 , ?̃? = 𝐷 − 𝑅𝑅
𝑇𝐷 and 𝐸?̃? = 𝐸𝑖 − 𝑅𝑅
𝑇𝐸𝑖, 𝑖 = 1,2,3. Next, 




























Figure 5: Power as a function of significance level for the four similarity-based tests and two 
rare variants pooling strategies when common variants were excluded from the analysis. 
Extracted from Zakharov et al.98 
Panel 1: “Risk Rare” Scenario; Panel 2: “Risk Both” Scenario; Panel 3: “Risk Common” Scenario; 
Panel 4: “Mixed Rare” Scenario.  
 













Figure 6: Empirical type-1 error rates for dichotomized adjusted quantitative phenotype in 
GAW17 data set at the theoretical level of 0.05 (ARNT-VEGFC with Q1, and BCHE-VWF 























Figure 7: Empirical type-1 error rates for dichotomized adjusted case-control status in 
GAW17 data set at the theoretical level of 0.05. Extracted from Zakharov et al.98 
The residuals from the regression models (18-20) were dichotomized (upper 30% 
of the observed distribution were declared cases, while the others were controls) 
and tested for association with adjusted genotype ?̃? of the causal genes. The type-
1 error rate was set at 0.05, and 1000 permutations were performed for each of the 
200 phenotype replicates to estimate power. To assess the empirical type-1 error 
rate for all the statistical tests we ran the analysis with randomly permuted 
adjusted phenotypes obtained from the regressions (18-20). The resulting type-1 






















for the type-1 error estimate is approximately 0.01–0.09. This can be derived from 
the normal approximation, given that the estimate of type-1 error rate is 
distributed as an observed probability of success for a binomial random variable 
with a success probability of 0.05 under no inflation of type-1 error and the 
sample size of 200, which is the number of phenotype replicates. As can be seen, 
the empirical type-1 error for GAW17 data was within the 99% confidence 
interval.  
Figure 8 depicts the results of the analysis of the causal genes with the respective 
phenotypes (ARNT-VEGFA with Q1, and BCHE-VWF with Q2). For the 
majority of genes with rare causal variants, the weighting strategy, on average, 
performed better than collapsing (except for MDMR). For example, the weighing 
strategy resulted in a substantial power improvement for the genes ARNT, SIRT1, 
VNN3 and VWF. All of these genes contained multiple causal rare variants with a 
moderate or high effect size. However, collapsing yielded a much higher power 
for ELAVL4 and VNN1 genes. Closer examination revealed that the two most 
common SNPs in the VNN1 gene were causal, whereas association with the 
ELAVL4 gene could be explained by association of the only two common SNPs 
that were non-causal. To show this, we analyzed these two common SNPs with 
the four similarity-based tests and found that the power to identify an association 
with a phenotype was as follows: MDMR – 0.6, SKAT – 0.585, KBAT – 0.135, 
U-test – 0.095. The results of the dichotomous phenotype analysis are presented 
in Figures 9-10. Among genes with the maximum achieved power of greater than 





Figure 8: Power to identify an association with dichotomized adjusted quantitative trait in 
GAW17 data set for causal genes (ARNT-VEGFA with Q1, and BCHE-VWF with Q2). 
Extracted from Zakharov et al.98 
 
 
Figure 9: Power to identify an association with dichotomized adjusted case-control status in 
GAW17 data set for causal genes that impact quantitative traits 𝑸𝟏or 𝑸𝟐. Extracted from 



















Figure 10: Power to identify an association with dichotomized adjusted case-control status in 
GAW17 data set for causal genes that impact only dichotomous trait 𝑫. Extracted from 
Zakharov et al.98 
whereas collapsing yielded higher power for FLT1 and PRKCA, which both 
contained common causal SNPs.  
So, the results of the GAW17 data set support the conclusion derived from 
population genetics simulations concerning pooling strategies. We also 
considered the maximum absolute difference in power between weighting and 
collapsing for each statistical test and each GAW17 phenotype (Q1, Q2 and 
dichotomous trait) over the respective causal genes. As can be seen from Table 5, 
the maximum absolute power difference ranged from 14.5% (U-test) to 84% 
(MDMR). The average maximum power differences across phenotypes were 
73.8%, 45.6%, 35.6% and 40.5% for MDMR, SKAT, KBAT and U-test, 
respectively. This observation highlights the importance of the right choice of rare 









Phenotype MDMR SKAT KBAT U-Test 
Q1 0.84 (KDR) 0.45 (ARNT) 0.22 (ARNT) 0.145 (HIF3A) 
Q2 0.605 (VNN1) 0.5 (VNN1) 0.42 (VNN1) 0.535 (VNN1) 
D 0.77 (FLT1) 0.42 (PRKCA) 0.43 (PRKCA) 0.535 (FLT1) 
Table 5: The maximum absolute difference in power (over the respective causal genes) 
between weighting and collapsing pooling strategies for different tests and phenotypes in 
GAW17 data set. Extracted from Zakharov et al.98 
The genes at which the maximum difference was achieved are in brackets. 
Discussion 
We compared the performance of four similarity-based tests together with two 
rare variants pooling strategies using population genetics simulations and the 
GAW17 data set. The results suggest that weighting may be a much better 
strategy than collapsing under the assumption of strong effect from rare variants, 
and moderate or low effect from common variants. Collapsing, in turn, showed 
much better performance when common variants possessed a strong effect. The 
absolute power difference of a statistical test when applied with collapsing and 
weighting pooling strategies may be substantial. Additionally, under strong rare 
variants effect size in one direction when common variants were excluded from 
the analysis, collapsing performed equally good or better than weighting. Finally, 
both SKAT and KBAT had consistently high power compared with other 
considered similarity-based tests when applied with the appropriate pooling 
strategy. Given that the underlying disease model is unknown in advance, it is 
recommended to apply either SKAT or KBAT test with both collapsing and 




Recently, Basu and Pan40 compared the performance of multiple statistical tests to 
identify an association with rare variants. The authors included SKAT with 
unweighted linear and quadratic kernels as one of the testing strategies. Based on 
their results, Basu and Pan40 concluded that SKAT was powerful compared with 
other methods when only rare variants were considered. However, the authors 
found that the method lost its high power when neutral common variants were 
added. Our results suggest that using weighted kernels in SKAT may preserve 
high power to identify an association with rare variants even if multiple neutral 
common variants are included in analysis. However, since we compared the 
performance of similarity-based tests, additional investigation is required to 
compare weighted similarity-based tests with other statistical strategies, including 
those considered in Basu and Pan.40 
From our results MDMR test did not seem to perform well when applied with 
weighting pooling strategy. To have a more detailed picture we applied weighted 
MDMR test to the “Risk Rare” simulated data sets with modified weights 𝑤𝑙
𝑝, 𝑙 =
1, … , 𝐿, where the power value 𝑝 varied from 0 to 1. So, 𝑝 = 1 corresponded to 
the beta weights applied in our study, whereas 𝑝 = 0 corresponded to the analysis 
without weights. Figure 11 shows the power surface as a function of significance 
level and a value of 𝑝. It is clear that for all significance levels power of MDMR 
monotonically decreased with higher values of 𝑝, which corresponds to higher 
relative weights for rare variants. In the Appendix to Chapter 2 it is proven that 
when the number of cases equals the number of controls (like in our simulations), 




Figure 11: Power of MDMR test (vertical axis) as a function of type-1 error and parameter 𝒑 
in modified weights for “Risk Rare” scenario. Extracted from Zakharov et al.98 
The modified weights are calculated as 𝑤𝑙
𝑝, 𝑙 = 1, … , 𝐿, where the parameter 𝑝 varies between 0 
(uniform weights) and 1 (beta weights as applied in the study). 
 
equivalent to the sum of and the sum of squares of dissimilarities for all case-
control pairs respectively. When weighting pooling strategy is applied, 
dissimilarity tends to be relatively large for pairs of individuals whose genotypes 
differ in multiple rare minor alleles. Squaring dissimilarity measure puts more 
emphasis on pairs with larger dissimilarity. Thus, the magnitude of the MDMR 
test statistic may be completely defined by the number of case-control pairs 
whose genotypes differ by at least two rare minor alleles. We suppose that pairs 
with a difference of one rare allele may not have sufficient dissimilarity to 
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significantly influence the MDMR test statistic, which leads to power loss. To 
illustrate our reasoning, let us have two rare variants with only eight observed 
minor alleles each across 500 cases and 500 controls. To simplify the description, 
assume that individuals have either zero or one copy of a minor allele across these 
two variants. Also, we will use the equivalence of the MDMR test statistic to the 
sum of squared case-control dissimilarities. Consider the following scenarios 
under the null and alternative hypotheses, respectively: cases and controls have 
four minor alleles for each variant, and cases have all minor alleles. Under the 
alternative hypothesis, we have zero case-control pairs with a difference of two 
alleles across genotype, whereas under the null hypothesis, we have 32. However, 
under the alternative hypothesis, there are 16 × 500 case-control pairs with a 
difference of one minor allele, whereas under the null hypothesis, there are only 
16 × (500−8). Now it becomes clear that if the dissimilarity for a pair of 
individuals with difference in two alleles is large enough relative to the 
dissimilarity for a pair of individuals with difference in only one allele, MDMR 
test statistic may become lower for the alternative scenario compared to those 
under the null scenario. The consideration above explains low performance of 
MDMR with weighted similarity and the fact that for the “Risk Rare” scenario the 
power of MDMR test was below type-1 error rate. 
One limitation of the current study is that the minimum significance level in 
population genetics simulations was 0.001. For genome-wide type-1 error rate the 
number of permutations needed to reliably estimate significance is very large. 
This makes the comparison of similarity-based tests at the genome-wide level 
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prohibitive. In real GWA studies only few highly-significant genes will require a 
very large number of permutations to estimate p-values, as many genes with low 
or no association signal can be dropped out after a few thousand permutations. 
For highly significant genes, permutation procedure can be split into several parts 
and performed in parallel on a cluster.  
Conclusions 
The performance of similarity-based tests applied with two rare variants pooling 
strategies was investigated. Population genetics simulations and sequencing data 
set analysis showed consistently high power of two similarity-based tests and a 












Chapter 3 – A method to incorporate prior information into score 
test for genetic association studies 
Background 
In spite of the success of genome-wide association studies (GWAS) in identifying 
hundreds of common single nucleotide polymorphisms (SNPs) associated with 
diseases and complex traits (http://www.genome.gov/gwastudies/), in many cases 
the proportion of heritability explained by these discovered SNPs is low.2; 101; 102 
One of the potential explanations of this observation is that rare variants (usually 
defined as those with minor allele frequency below 1%), which are absent from 
conventional GWAS studies, are responsible for the missing heritability. Indeed, 
there is strong evidence that rare variants are associated with some complex 
traits.12-14; 20; 22  
When performing rare variants association analysis researchers face significant 
methodological challenges. The single SNP approach, which is popular in GWA 
studies, is underpowered when applied in rare variants association studies with 
moderate sample size due to low allele count for each individual rare variant. To 
overcome this problem, testing multiple rare variants within a region has been 
recommended,28; 29 and a number of region-based rare variants tests have been 
proposed.24; 33; 35; 74; 103 However, these novel methodologies may still be 
underpowered for association studies with moderate sample size.104 This 
motivates the development of statistical methods that utilize prior information 
with the purpose of improving power. Currently, much biological information is 
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publicly available, such as the prediction of degree of deleteriousness of non-
synonymous variants (PolyPhen http://genetics.bwh.harvard.edu/pph2/, SIFT 
http://sift.bii.a-star.edu.sg/), SNP prioritization (FastSNP http://fastsnp.ibms. 
sinica.edu.tw), functional SNP annotation (SNPnexus http://www.snp-nexus.org/) 
etc. Although several methods that use prior information have been proposed,56; 
105-107 further research is needed to utilize prior knowledge more efficiently108 and 
to expand statistical tools available for researchers.  
In this chapter we propose a method that incorporates prior information into the 
region-based score test. Within our framework, prior information is used to 
partition SNPs within a genomic region of interest into groups. Then within each 
group asymptotically independent SNP scores are combined into a one degree of 
freedom (d.f.) chi-squared statistics. These group statistics are then used to 
construct a global test for a region. The proposed methodology has several 
distinct advantages. First of all, the degrees of freedom of our test statistic equals 
to the number of groups, which may be much less than the number of SNPs 
within a region. Secondly, under partitioning that approximately separates 
associated variants from neutral ones (“informative” partitioning) the proposed 
method efficiently handles noise introduced by neutral variants. We have 
evaluated the performance of our method on theoretical power comparison, 
population genetics simulations and analysis of the GAW17 
(http://www.gaworkshop.org/gaw17/) real sequencing data set. The results 
showed that under some scenarios the proposed methodology performed as well 




Consider a rare variants association study of a genomic region with a 
dichotomous or quantitative trait. Let us introduce the following notations: 
genotype matrix 𝐺 = {𝑔𝑛𝑙, 𝑛 = 1, … , 𝑁, 𝑙 = 1, … , 𝐿} coded as minor allele counts, 
where 𝑛 and 𝑙 are indices for individuals and variants respectively; 𝑁 × 1 vector 
of genotypes for the 𝑙th variant 𝑔𝑙 = {𝑔𝑛𝑙, 𝑛 = 1, … , 𝑁}; mean of genotype for the 
𝑙th variant 𝑔?̅?; phenotype vector 𝑌 = {𝑦𝑛, 𝑛 = 1, … , 𝑁}, mean of phenotype ?̅?. 
Consider the generalized linear model 𝑔(𝐸𝑦) = 𝑏0 + 𝐺𝑏, where 𝑏 = {𝑏1, … , 𝑏𝐿} 
is a vector of regression coefficients, and 𝑔 is a monotone link function. The score 




where 𝑈 = {∑ (𝑦𝑛 − ?̅?)(𝑔𝑛𝑙 − 𝑔?̅?)
𝑁
𝑛=1 }𝑙=1
𝐿 is the vector of scores, 𝑉 =
𝐶𝑜𝑣(𝐺) ∑ (𝑦𝑛 − ?̅?)
2𝑁
𝑛=1  is 𝐿 × 𝐿 the score covariance matrix assumed to be non-
singular, and 𝐶𝑜𝑣(𝐺) = {𝐶𝑜𝑣(𝑔𝑙, 𝑔𝑙′)}𝑙,𝑙′=1
𝐿  is the 𝐿 × 𝐿 genotype covariance 
matrix. Under the null hypothesis (none of the variants is associated with 
phenotype) 𝑇0 asymptotically follows chi-squared distribution with 𝑟𝑎𝑛𝑘(𝑉) 
degrees of freedom (d.f.). Under the alternative hypothesis (at least one variant is 
associated with phenotype) the asymptotic distribution of (21) can be 
approximated by a non-central chi-squared distribution. 
Following is the description of our proposed method. First, let us transform the 
coordinates of score vector 𝑈 to be asymptotically independent under the null 
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hypothesis. If we denote 𝐶 = (𝐴𝑇)−1, where matrix 𝐴 is a Cholesky 
decomposition of 𝑉 (𝑉 = 𝐴𝑇𝐴), the vector 𝑆 = 𝐶𝑈, under the null hypothesis, is 
asymptotically distributed as a standard multivariate normal random vector (since 
𝐶𝑜𝑣(𝐶𝑈) = 𝐶𝐶𝑜𝑣(𝑈)𝐶𝑇 = (𝐴𝑇)−1𝑉𝐴−1 = (𝐴𝑇)−1(𝐴𝑇𝐴)𝐴−1 = 𝐼). It should be 
noted that under the alternative hypothesis S is approximately distributed as a 
multivariate normal random vector with nonzero mean and unit covariance matrix 
under the assumption of 𝑉 being a reasonable approximation for the covariance 
matrix of 𝑈.110 In general, any other decomposition of the covariance matrix 𝑉 of 
the form 𝑉 = 𝐴𝑇𝐴 can be used. We apply Cholesky decomposition because it is 
fast to compute even for big covariance matrices.  
Next, let us describe group statistics. Consider partitioning of 𝐿 SNPs within a 
region into 𝐾 disjoint groups 𝐺𝑘, 𝑘 = 1, … , 𝐾of size 𝐿𝑘, 𝑘 = 1, … , 𝐾. This 
partitioning is done using prior information, for example: by observed MAF 
(below and above some arbitrary frequency threshold); by functional annotation 
(non-synonymous and synonymous for exon sequencing studies; exonic, intronic, 
3’UTR, 5’UTR and intergenic for gene-based studies); by functional significance 
for non-synonymous SNPS (benign, probably and possibly damaging from SIFT 
or PolyPhen output) etc. For each group let us define 𝑡𝑘 = ∑ 𝑠𝑙
2
𝑙∈𝐺𝑘 , 𝑘 = 1, … , 𝐾, 
where 𝑠𝑙 , 𝑙 = 1, … , 𝐿 is the 𝑙th coordinate of the vector 𝑆. It should be noted that 
partitioning based on prior information can be applied to 𝑆, since 𝑆 = (𝐴𝑇)−1𝑈 is 
the vector 𝑈 in a new basis, which is the set of column vectors of the matrix 𝐴𝑇 
(old basis is a standard basis). Since the vector 𝑆 is multivariate normal with unit 
covariance matrix, 𝑡𝑘 , 𝑘 = 1, … , 𝐾 are asymptotically independent. Under the null 
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hypothesis 𝑡𝑘 asymptotically follows central chi-squared distribution with 𝐿𝑘 
degrees of freedom, whereas under the alternative hypothesis at least one of the 
𝑡𝑘, 𝑘 = 1, … , 𝐾 is distributed as a non-central chi-squared random variable. Let us 
denote as 𝑃𝑙 and 𝑃𝑙
−1 cumulative distribution function (CDF) of central chi-
squared random variable with 𝑙 d.f. and its inverse respectively. Group statistics 
𝐻𝑘 are defined as follows: 
𝐻𝑘 = 𝑃1
−1 (𝑃𝐿𝑘(𝑡𝑘)). (22) 
It should be noted that under the null hypothesis 𝐻𝑘 follows a central chi-squared 
distribution with 1 d.f. Finally, the test statistic of our proposed method is: 
𝑇1 = ∑ 𝐻𝑘
𝐾
𝑘=1
 . (23) 
Under the null hypothesis 𝑇1 is distributed as a chi-squared random variable with 
𝐾 d.f. Large value of 𝑇1 indicates the deviation from the null hypothesis. 
Transformation (22) is used to decrease the degrees of freedom of the final test, as 
some of the groups 𝐺𝑘, 𝑘 = 1, … , 𝐾 may contain only neutral variants. If 𝑘th 
group does not contain associated SNPs, group 𝐺𝑘 contributes only 1 d.f. to the 
final test, whereas it adds 𝐿𝑘 d.f. to the score test. Thus, under “informative” 
partitioning our proposed method may gain power compared with the score test.  
There are few notes that should be taken into account when applying our method. 
First, the theoretical approximation for distribution of 𝑡𝑘 may not hold under 
moderate sample sizes. Hence, in all our simulations and real data application we 
used the empirical CDF of 𝑡𝑘, denoted as 𝐹𝑘, obtained via 1000 permutations 
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under the null hypothesis. Instead of 𝑃𝐿𝑘(𝑡𝑘) in (22) we calculated a Gaussian 
kernel CDF estimate 𝐹𝑘(𝑡𝑘) with a multi-stage plug-in bandwidth of Polansky and 
Baker.111 R (http://cran.r-project.org) package ‘kerdiest’ contains all the necessary 
algorithms. Second, the covariance matrix 𝑉 may happen to be computationally or 
exactly singular when, for example, considering a region with high LD between 
common SNPs. In general, to avoid singularity issues we apply Monroe-Penrose 
pseudoinverse in (21) instead of 𝑉−1. This pseudoinverse is uniquely defined and 
equals the standard inverse matrix when 𝑉 is non-singular. From the same 
considerations instead of usual Cholesky factoring we used generalized Cholesky 
decomposition, which is well defined for square symmetric positive semi-definite 
matrices. If 𝑉 is non-singular, the generalized Cholesky decomposition equals the 
usual Cholesky factoring. Also, it should be noted that in general our test statistic 
is not invariant with respect to the ordering of variants within a region. To clarify 
the ambiguity we assume the ordering of SNPs according to a position on a 
chromosome (see the “Discussion” section). 
Theoretical power calculations 
To evaluate our method we compared its theoretical power with those of the score 
test. Denote the non-centrality parameter (NCP) of the test statistic (21) under the 
alternative hypothesis as 𝑟 (the connection between 𝑟 and effect size is provided 
in Appendix to Chapter 3). Also, we will use the notations 𝑃𝑙,𝑟 and 𝑃𝑙,𝑟
−1 for the 
CDF of non-central chi-squared random variable with 𝑙 d.f. and NCP 𝑟 and its 
inverse respectively. The power of the score test with type-1 error rate 𝛼 is: 
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1 − 𝑃𝐿,𝑟(𝑞1−𝛼,𝐿), (24) 
where 𝑞1−𝛼,𝐿 is 1 − 𝛼 quantile of the chi-squared distribution with 𝐿 d.f. Let us 
assume that all the causal SNPs are uncorrelated with other SNPs within a region, 
and that they are in one of the 𝐾 groups (without loss of generality, let it be the 
first group 𝑘 = 1). Then, the power of the proposed test is: 
1 − 𝑃(𝐻1 + 𝜒𝐾−1
2 < 𝑞1−𝛼,𝐾), (25) 
since ∑ ℎ𝑘
𝐾
𝑘=2  follows a central chi-squared distribution with 𝐾 − 1 d.f., because 
all associated SNPs are in the first group. The probability in (25) can be computed 
using the convolution of two CDFs as follows: 
𝑃(𝐻1 + 𝜒𝐾−1




Under the alternative hypothesis non-centrality parameter of 𝑇0 and those of 𝑡1 
are equal, since both statistics include all the associated SNPs within a region. 
Thus, the distribution of 𝐻1 is 𝑃1
−1 (𝑃𝐿1(𝜒𝐿1,𝑟
2 )), and the integrand in the equation 
(26) can be calculated as 𝑃(𝐻1 < 𝑞1−𝛼,𝐾 − 𝑥) = 𝑃𝐿1,𝑟 (𝑃𝐿1
−1 (𝑃1(𝑞1−𝛼,𝐾 − 𝑥))). 
This allows us to compute the theoretical power of our method.  
Population genetics simulations 
Boyko et al96 found a simple two-epoch expansion model to be one of the best-fit 
models for population genetics simulations of African-American genotype. Also, 
the authors found strong evidence of selective effects acting on new amino acid 
replacing mutations and inferred the distribution of those selective effects. The 
scaled population selection coefficient (defined as a selection coefficient 
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multiplied by twice the effective population size) was assumed to follow a 
negative gamma distribution with the following parameters: shape 0.184 and scale 
8200. Mutation rate was set at 1.8 × 10−8 per nucleotide per generation. The 
selective disadvantage was additive. Using the forward simulator SFS_CODE 
(http://sfscode.sourceforge.net) with the parameters described above, we 
generated 100 haplotype pools for a 3kb coding genomic region. Each haplotype 
pool contained 4000 haplotypes. In our simulations we considered only non-
synonymous variants. To generate a data replicate we first selected a haplotype 
pool at random. Within that pool we sampled a pair of haplotypes at random and 
added those haplotypes to form a multi-site genotype of an “individual”. 
Dichotomous phenotype was assigned based on this multi-site genotype using a 
linear logistic model through which we controlled the odds ratios of causal 
variants. The probability of a disease conditional on the wild type genotype was 
set at 1% for all phenotype models.  
We considered four phenotype scenarios. For the first model called “Rare” 
randomly chosen 50% of rare variants (defined as those with MAF<1%) within a 
haplotype pool were assigned to be causal with uniform odds ratio of 3. For the 
“Low Frequency” scenario one randomly chosen low frequency SNP (MAF 
between 1% and 5% in a haplotype pool) was causal with odds ratio of 2.5. If 
there was no SNP with MAF between 1% and 5% in a haplotype pool, we 
selected a SNP with the lowest MAF above 5%. For the “Common” scenario one 
common SNP with MAF>5% in a haplotype pool was causal and had the odds 
ratio of 1.5. Finally, the “Interaction” scenario models the hypothesized 
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interaction of common and rare variants in RET gene associated with 
Hirschsprung’s disease.112; 113 The simulation framework for this scenario was 
previously described by Liu and Leal.79 Briefly, 50% of rare variants were 
assigned to be causal. Each causal rare minor allele increased the odds of a 
disease by 6 times if and only if it was present on the same haplotype as a minor 
allele of a common SNP randomly chosen beforehand.  
Sample sizes were the following: 500 cases and 500 controls for “Rare”, “Low 
frequency” and “Common” scenarios; 1000 cases and 1000 controls for 
“Interaction” model. In total 1000 data replicates were generated for each 
scenario. Power was estimated as a proportion of data replicates significant at a 
fixed type-1 error of 0.05. For all the statistical tests 1000 permutations were 
applied to estimate a significance level. 
Results 
Theoretical power comparison 
Figure 12 shows the difference between the theoretical power of the proposed 
method and those of the score test for different scenarios at the fixed type-1 error 
rate of 0.05. For Panel 1 of Figure 12, the number of SNPs within a region 𝐿 =
10, the number of groups in a partitioning 𝐾 = 2, the range of values for the non-
centrality parameter (NCP) 𝑟 0–30 (x-axis), and the number of variants in a causal 
group 𝐿1 = 2, 4, 6, 8 (different values of 𝐿1 correspond to different curves). As 
can be seen, the power gain of the proposed method reached as high as 15 percent 





Figure 12: The difference in theoretical power (vertical axis) of the proposed test and the 
score test as a function of the total non-centrality parameter 𝒓 (horizontal axis) at the type-1 
error rate 𝜶 = 𝟎. 𝟎𝟓. Adapted from Zakharov et al.114 
Each curve corresponds to the number of SNPs in the single causal group 𝐿1 given in the legend 
(Panels 1 and 2), the number of groups 𝐾 (Panel 3), and the number of causal groups 𝑚 (Panel 4). 
The parameters for each of the Panels are as follows:  
Panel 1: 𝐿 = 10, 𝐾 = 2;  
Panel 2: 𝐿 = 100, 𝐾 = 10;  
Panel 3: 𝐿 = 50, 𝐿1 = 5;  
Panel 4: 𝐿 = 54, 𝐾 = 6, equal number of SNPs in each group, and equal non-centrality parameters 






However, the power of the proposed test was lower than those of the score test 
when 𝐿1 was large. This can be explained from the formula (22), which implies 
that with an increase in the number of variants in a causal group 𝐿1 and fixed 
NCP 𝑟 the value of the group statistic 𝐻1 monotonically decreases. Also, it is 
noticeable that with an increase in NCP 𝑟 up to some point the power difference 
also increased when 𝐿1 was small, whereas the power difference decreased for 
large values of 𝐿1. For very large values of NCP 𝑟 the power difference became 
close to 0 as theoretical powers of both tests tended to 1. Similar conclusions can 
be obtained from Panel 2 of Figure 12 which shows the results for the scenario 
with the following parameters: 𝐿 = 100, 𝐾 = 10, varying NCP 𝑟 (x-axis), and 
varying 𝐿1 = 10, 20, 30, 40. 
To investigate the impact of the number of groups 𝐾 on power the following 
model was considered (Panel 3 of Figure 12): 𝐿 = 50, 𝐿1 = 5, and 𝐾 =
8, 16, 24, 32. As can be seen, the power difference is below zero for large values 
of 𝐾 and above zero for small values of 𝐾. This may be explained by the fact that 
the test statistic 𝑇1 (23) is distributed as chi-squared random variable with 𝐾 d.f. 
Thus, for the fixed NCP 𝑟 and increasing value of 𝐾 the power of the proposed 
method monotonically decreases. 
Alongside the models considered above, it is important to include a scenario when 
causal variants are split between several groups. Panel 4 of Figure 12 depicts the 
power difference under the following model: 𝐿 = 54, 𝐾 = 6, and the number of 





Figure 13: The difference in theoretical power (vertical axis) between the proposed test and 
the score test as a function of the total non-centrality parameter 𝒓 (horizontal axis) at the 
genome-wide type-1 error rate 𝜶 = 𝟎. 𝟎𝟓/𝟑𝟓𝟎𝟎𝟎. Adapted from Zakharov et al.114 
Each curve corresponds to the number of SNPs in the causal group L1 given in the legend (Panels 
1 and 2), number of groups 𝐾 (Panel 3), and number of causal groups 𝑚 (Panel 4). The parameters 
for each of the Panels are as follows:  
Panel 1: 𝐿 = 10, 𝐾 = 2;  
Panel 2: 𝐿 = 100, 𝐾 = 10;  
Panel 3: 𝐿 = 50, 𝐿1 = 5;  
Panel 4: 𝐿 = 54, 𝐾 = 6, equal number of SNPs in each group, and equal non-centrality parameters 






Also, for simplicity of presentation it was assumed that each group contained 
equal number of variants (54/6 = 9), and NCP 𝑟 was split equally between all 
causal groups.  For this scenario the calculation of theoretical distribution of  𝑇1 
(23) was done using 500,000 simulations of test statistics under the alternative 
hypothesis, as equation (25) cannot be used here. As can be seen from Panel 4 of 
Figure 12, our methodology could gain power if associated SNPs were split 
between several groups. When the number of causal groups became large, our 
method was slightly worse than the score test. It should be noted that for all 
models the maximum power gain of our method (and equivalently the maximum 
power loss) was achieved when the power of the score test was around 50%. 
Conclusions similar to those above can be derived from Figure 13 which shows 
the same scenarios for the fixed type-1 error rate set at the genome-wide level 
assuming 35,000 genes (𝛼 = 0.05/35000). 
Population genetics simulations results 
Using population genetics simulations we compared our method with the score 
test and other proposed approaches, namely, weighted selective collapsing 
strategy (WSCS),34 variable threshold (VT),56 weighted sum of squared scores test 
(SSUw),40 and optimal sequence kernel association test (SKAT-O) with linear 
kernel and beta weights.51 Since these tests utilize only genotype and phenotype 
information, we applied our method with MAF (minor allele frequency) 
partitioning: variants within a region are divided into two groups, namely, those 
with observed MAF above and below 1%. To estimate the empirical type-1 error 





Figure 14: The estimate of empirical type-1 error rate of the proposed method with MAF 
partitioning, the score test, VT, WSCS, SSUw and SKAT-O for population genetics 
simulations. Extracted from Zakharov et al.114 
The theoretical type-1 error was assumed to be 0.05. The data for the estimate of the type-1 error 




Figure 15: Comparison of the proposed method with MAF partitioning and other statistical 
tests on population genetics simulations. Extracted from Zakharov et al.114 
In the “Rare” phenotype model only rare variants (MAF<1% in haplotype pool) were causal with 
uniform effect size. “Low Frequency” and “Common” phenotype models had only one low 
frequency (MAF between 1% and 5%) and one common (MAF>5%) causal SNP respectively. 
Finally, the “Interaction” scenario models the interaction of rare variants with a common SNP. A 
minor allele of a rare causal variant had an impact on phenotype if and only if it was present on the 








As can be seen from Figure 14, the type-1 error was well controlled for all the 
tests. Figure 15 shows the results of the population genetics simulations. As can 
be seen, our method was the most powerful for both “Low Frequency” and 
“Common” phenotype models, closely followed by WSCS and SSUw 
respectively. For the “Interaction” model WSCS achieved slightly higher power 
than other methods. For the “Rare” model WSCS and VT tests showed the highest 
power, whereas our method performed worse than most other methods. Although 
in this scenario all the causal variants had MAF < 1% in a haplotype pool, some 
of the causal variants were expected to have MAF > 1% in a data replicate, since 
causal alleles increased the probability of a disease. Thus, in this case applying 
MAF partitioning could result in causal variants with high MAF being combined 
with neutral common SNPs.  
GAW17 analysis results 
In addition to theoretical power comparison and population genetics simulations 
we also used the GAW17 data set to compare our test with other methods. The 
GAW17 data set was designed to mimic a real exome sequencing study of a 
complex disease. Full description of the method used to generate the GAW17 data 
can be found in Almasy et al.99 Briefly, the whole-exome sequencing data from 
1000 Genomes Project (http://www.1000genomes.org) was the basis for 
simulation of 200 replicates of dichotomous phenotype and 200 replicates of 3 
quantitative traits (endophenotypes) in 697 unrelated individuals from six 
populations (Chinese, Japanese, Yoruba, Luhya, Utah residents with Northen and 
Western European ancestry – CEPH, and Tuscan). Causal variants were chosen to 
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be common and rare non-synonymous SNPs concentrated in genes from specific 
pathways. Also, dichotomous phenotype and quantitative traits were impacted by 
covariates such as smoking status, gender and age. We conducted an association 
analysis of known causal genes with two quantitative traits (third quantitative trait 
was simulated independently from genotype) and a dichotomous phenotype 
adjusting for covariates and population stratification. The adjustment procedure 
was similar to those described by Jiang and Dong.100 Let 𝐺 be the genotype 
matrix of a gene under investigation; 𝑄1, 𝑄2, 𝐷 – vectors of two quantitative traits 
and  a dichotomous phenotype respectively; 𝐸𝑖, 𝑖 = 1,2,3 –  vectors of age, gender 
and smoking status respectively; 𝑅 – matrix of ten principal components obtained 
from Eigenstrat.49 First, phenotypes, genotype and covariates were adjusted for 
population stratification as follows: adjusted genotype ?̌? = 𝐺 − 𝑅𝑅𝑇𝐺; adjusted 
phenotypes 𝑄1̃ = 𝑄1 − 𝑅𝑅
𝑇𝑄1, 𝑄2̃ = 𝑄2 − 𝑅𝑅
𝑇𝑄2, ?̃? = 𝐷 − 𝑅𝑅
𝑇𝐷; adjusted 
covariates 𝐸?̃? = 𝐸𝑖 − 𝑅𝑅
𝑇𝐸𝑖, 𝑖 = 1,2,3. Second, covariates were regressed out 
from adjusted phenotypes using the following models: 
𝑄1̃ = 𝑎0 + ∑ 𝑎𝑖𝐸?̃? +
3
𝑖=1








where 𝑞1, 𝑞2 and 𝑑 are regression residuals. These residuals were tested for an 
association with adjusted genotype ?̃?. Statistical significance for each method was  
assessed using 1000 permutations. The power was calculated as a proportion of 
phenotype replicates significant at the type-1 error rate of 0.05.  
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GAW17 analysis results: comparison with the score test 
 
Figure 16: The estimate of empirical type-1 error rate of the proposed method with different 
partitionings and those of the score test for the causal genes in GAW17 data. Extracted from 
Zakharov et al.114 
The theoretical type-1 error was assumed to be 0.05. Panel 1: 𝑄1 and 𝑄2 causal genes and 
respective quantitative trait (𝑄1 causal genes are those from ARNT to VEGFA, 𝑄2 causal genes 
are those from BCHE to VWF); Panel 2: causal genes and dichotomous trait.  
 
We considered three partitionings for our method: MAF partitioning (two groups: 
variants with MAF above and below 1%), functional partitioning (two groups: 
non-synonymous variants; synonymous and unknown variants), and combined 
partitioning (four groups defined by MAF and functionality). To assess the 
empirical type-1 error rate of our method and those of the score test we ran the 






















shows the empirical type-1 error rates for 𝑄1 and 𝑄2 traits (Panel 1) and 
dichotomous phenotype (Panel 2). It should be noted that the estimate of type-1 
error rate is distributed as an observed probability of success for a binomial 
random variable with the sample size of 200 (number of phenotype replicates) and 
the probability of success 0.05 (theoretical type-1 error rate). The two-sided 99% 
confidence interval for the estimate of type-1 error rate is 0.015–0.095. As can be 
seen from Figure 16, the type-1 error was well controlled.  
Panel 1 of Figure 17 shows the results for our method and the score test on genes 
that impacted 𝑄1 and 𝑄2 (genes from ARNT to VEGFA were tested on 
association with 𝑄1, genes from BCHE to VWF – with 𝑄2). Panel 2 of Figure 17 
depicts the results of the analysis for the dichotomous trait. As can be seen, the 
score test was significantly more powerful for KDR, BCHE and SOS2 genes 
(dichotomous phenotype), whereas for at least one partitioning the proposed 
method was substantially more powerful for ARNT, ELAVL4, HIF1A genes (𝑄1 
trait); VNN1 gene (𝑄2 trait); FLT1 and PIK3C3 genes (dichotomous phenotype). 
Table 6 shows our suggested reasons for the difference in performance between 
the score test and our proposed method for the genes listed above. As can be seen, 
for all the genes for which our method outperformed the score test, some of the 
considered partitionings contained a group consisting of only associated variants. 
This is likely to have resulted in our method achieving higher power compared 
with those of the score test. It should be noted that for ELAVL4 gene the major 
association signal is borne by common variants, although according to the 




Figure 17: Results of GAW17 analysis – comparison of the proposed method with the score 
test on causal genes and with other methods on 𝑸𝟏 causal genes. Extracted from Zakharov et 
al.114 
Panel 1: Comparison of the proposed method (with different partitionings) with the score test for 
𝑄1 and 𝑄2 causal genes and respective quantitative traits (𝑄1 causal genes are those from ARNT to 
VEGFA, 𝑄2 causal genes are those from BCHE to VWF); Panel 2: Performance of the proposed 
method (with different partitionings) and the score test for the causal genes and a dichotomous 





















Suggested reason for the difference in 
performance. 




All common non-synonymous SNPs are causal. 
ELAVL4 MAF 
Association of the three common non-causal SNPs 
with 𝑄1*. 
HIF1A MAF The only common SNP is causal. 








All common non-synonymous SNPs are causal. 





No clear separation of associated variants from 
neutral ones using any of the considered 
partitionings. 
Table 6: Suggested reasons for the difference in power between the score test and our 
approach for some genes. Extracted from Zakharov et al.114 
The table contains only those genes for which there was a significant difference in performance 
between the score test and our approach for any of the suggested partitionings. 
* for details, see the subsection “GAW17 analysis results: comparison with the score test”. 
 
this hypothesis, we performed an association analysis of ELAVL4 common SNPs 
with 𝑄1 trait using the score test. The power to identify an association was 79% 
after adjusting for population stratification and confounders. For the genes KDR, 
BCHE and SOS2 we did not observe any clear separation of associated variants 
using any of the considered partitionings.  
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GAW17 analysis results: comparison with other tests 
We contrasted the performance of our method (MAF partitioning) with those of 
WSCS,34 VT,56 SSUw40 and SKAT-O with linear kernel and beta weights.51 Also, 
we included some of the published results obtained by the participants of the 
GAW17 workshop: the performance of Multivariate Distance Matrix Regression 
(MDMR) and Mantel tests on 𝑄2 causal genes,
115 the performance of aggregated 
U-test (AggregateU) and CMC method (QuTie) on 𝑄1 causal genes.
45 It should be 
noted that the adjustment for covariates and population stratification for SKAT-O 
test was done via the function “SKAT_Null_Model” of the R (http://cran.r-
project.org) package “SKAT”. Also, in our implementation of the WSCS method 
rare variant weights were proportional to the absolute value of correlation 
between those rare variants and phenotype, since the original weights described 
by Dai et al34 were not applicable due to the adjusted phenotype being 
quantitative. Figure 18 shows the empirical type-1 error estimates for WSCS, VT, 
SSUw and SKAT-O tests. Given that the 99% confidence interval for the 
empirical estimate of type-1 error rate is 0.015–0.095 as described previously, 
there was no evidence for type-1 error inflation.  
Panel 3 of Figure 17 depicts the analysis results for 𝑄1 causal genes. As can be 
seen, our method was among the top three most powerful approaches for ANRT, 
ELAVL4 and HIF1A genes. Panel 1 of Figure 19 shows the results for 𝑄2 causal 
genes. Our method was the top performer for VNN3 gene, and was among the top 
three performing approaches for LPL and VNN1 genes. Panel 2 of Figure 19 
depicts the results of an association analysis of all causal genes with dichotomous 
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phenotype. As can be seen, SKAT-O achieved the most notable power gains for 
PIK3C3 and PTK2B genes. This emphasizes that SKAT-O may significantly 
outperform other tests under some phenotype models. However, this method also 
may significantly underperform other tests for some phenotype models, for 
example, ELAVL4 gene with 𝑄1 trait and VNN1 gene with 𝑄2 trait. Our proposed 
method was among the top three performing methods for SOS2, PTK2B, PRKCA 
genes and some other genes for which the power of all the methods was low. 
 
Figure 18: The estimate of empirical type-1 error rate of WSCS, VT, SSUw and SKAT-O 
tests for the causal genes in GAW17 data. Extracted from Zakharov et al.114 
The theoretical type-1 error was assumed to be 0.05. Panel 1: 𝑄1 and 𝑄2 causal genes and 
respective quantitative trait (𝑄1 causal genes are those from ARNT to VEGFA, 𝑄2 causal genes 
























Figure 19: Results of GAW17 analysis – comparison of the proposed method with other 
methods on 𝑸𝟐 and 𝑫 causal genes. Extracted from Zakharov et al.
114 
Panel 1: Comparison of the proposed method (MAF partitioning) with other methods on 𝑄2 causal 
genes; Panel 2: Comparison of the proposed method (MAF partitioning) with other methods on 
causal genes and a dichotomous phenotype. 
 
Discussion 
In this chapter we have described a methodology that incorporates prior 
information into a region-based score test with the purpose of improving power to 
identify an association. Prior information, such as observed MAF, functional 
annotation, predicted deleteriousness of non-synonymous variants, may be used to 














construct a test statistic whose distribution under the null hypothesis has lower 
degrees of freedom compared with those of the score test. Based on the theoretical 
power comparison, population genetics simulations and GAW17 sequencing data 
analysis, we have shown that under some scenarios our method may perform as 
well as or outperform other methods. 
Our suggested partitioning is splitting by functionality and if rare variants are 
present – by MAF with an arbitrary threshold, e.g., 1%. One of the major 
justifications for considering MAF in a partitioning design is that MAF may 
distinguish between different evolutionary forces acting on causal variants. 
Evolutionary theory predicts that variants that confer susceptibility to a disease 
which in turn reduces fitness are expected to have low MAF due to purifying 
selection. Empirically, using whole-exome sequencing data, it was found that 
non-synonymous substitutions are more significantly skewed towards low 
frequencies compared with synonymous variants. This finding “almost certainly 
reflects the operation of purifying selection”5 acting on many genes across 
genome. Thus, if a causal gene is under strong purifying selection incorporating 
MAF into partitioning design is likely to be beneficial. On the other hand, a causal 
variant could have risen to higher frequency due to other forces such as balancing 
selection, mutation-selection balance, antagonistic pleiotropy, etc.116 Thus, for 
example, if a causal variant has been under a strong balancing selection it is likely 
to be common; and incorporating MAF into partitioning design may lead to power 
improvement. Partitioning by functionality may be beneficial for gene-based 
analysis in cases when an association signal comes from one or several functional 
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groups of variants. For example, if highly deleterious non-synonymous variants 
within exons of a gene are causal, then partitioning by functionality is likely to 
improve power. Although the misclassification rate for prediction tools may be 
high (e.g., PolyPhen-2 achieved 92% power to detect truly damaging variants at 
20% type-1 error rate over HumDiv data64), our method may still benefit from 
grouping variants by functional significance, since this is an effective way to give 
more emphasis on variants that are more likely to be causal.117 The benefit of 
using functional information was demonstrated in several simulations and 
candidate gene sequencing studies.56; 80; 118  
There are a few limitations of the proposed methodology. First, it is unknown in 
advance which prior information is relevant for a given genomic region. Prior 
information that does not help to uncover groups of associated variants is likely to 
have negative impact on statistical power. Second, the test statistic (23) is, in 
general, not invariant with respect to the ordering of SNPs. This can be seen, for 
example, when the covariance matrix 𝑉 is invariant with respect to permutation of 
elements of the score vector 𝑈 (e.g., all the cross-SNP covariances are the same, 
and diagonal variances are equal). So, for any SNP ordering the Cholesky 
decomposition 𝐴 is the same; hence, the test statistic is, in general, dependent on 
ordering. To clarify the ambiguity the ordering of SNPs according to a position on 
a chromosome may be assumed. 
Conclusions 
A novel statistical approach that incorporates prior information in a region-based 
score test with the purpose of improving power has been proposed. Theoretical 
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power comparison, population genetics simulations and the results of the GAW17 
data set analysis showed that under some scenarios our method may perform as 


















Chapter 4 – Combined genotype and haplotype tests for region-
based association studies 
Background 
The development of genotyping and sequencing technologies has enabled 
scientists to investigate the impact of genomic loci on complex disorders and 
traits. Indeed, genome-wide association studies (GWAS) and sequencing studies 
have identified many common single-nucleotide polymorphisms (SNPs) (for 
GWAS publication list, see http://www.genome.gov/gwastudies) and rare 
variations associated with common diseases.15; 18; 21; 89 Although single-SNP 
analysis has proven to be useful in discovering many disease-associated loci, this 
strategy may be limited due to very stringent significance threshold and poor 
reproducibility.95 Region-based association studies have the advantages of less 
stringent significance level and potentially higher power if multiple associated 
variants are found within a region. Indeed, several empirical studies have 
demonstrated the superiority of genotype gene-based association analysis over 
single-SNP strategy. 119; 120 Also, there is theoretical121; 122  and empirical evidence 
that haplotype-based tests may possess higher power than SNP-based tests. When 
intending to use haplotypes in an association study, one faces a problem of phase 
inference. While several statistical algorithms have been developed to infer 
unknown haplotypes from genotype data,68; 69; 123 improvements of sequencing 
technologies are likely to enable researchers to assemble haplotypes from 
sequencing data with very high accuracy (for examples of existing assembly 
algorithms, see Bansal et al,71 Bansal et al,72 and Schatz et al73). This opens up the 
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opportunity to use high-quality haplotypes and genotypes in sequencing 
association studies.  
Numerous studies have reported cases when haplotype-based analysis resulted in 
detection of an association, while SNP-based analysis either did not yield any 
significant results or yielded much higher p-values.124-127 A haplotype-based test 
may be more powerful than a genotype-based test if haplotypes tag a true causal 
variant better (although imputation of untyped SNPs using publicly available 
reference panels may also be a powerful strategy), or if a SNP-SNP interaction is 
present within a region. In general, it is unknown whether haplotype- or genotype-
based tests are more relevant for identifying an association of a genomic region 
with a phenotype. Thus, we propose two statistical tests that explicitly combine 
both genotype and haplotype information for the purpose of preserving high 
power under both genotype and haplotype disease scenarios. We investigate two 
methods based on a combination of p-values from genotype- and haplotype-based 
association tests. The first method is a minimum of p-values (MinP-val), and the 
other is a sum test statistic based on inverse standard normal transformation of 
two p-values (SumP-val). Based on simulations, theoretical power calculations 
and application to a GWAS data set, we have highlighted the merits and the 
drawbacks of genotype- and haplotype-based tests, and those of our combined 
approaches. The major conclusions from our work are as follows: 
 Combination of  haplotype- and genotype-based test statistics may 
preserve power for both genotype and haplotype disease models; 
80 
 
 In some of the considered scenarios, the performance of MinP-val and 
those of SumP-val are comparable; 
 MinP-val is much more robust than SumP-val when one of the underlying 
tests has low power. 
Methods 
Genotype- and haplotype-based tests 
Let us assume that we are interested in testing the joint association of all the 
variants within a genomic region with either a dichotomous phenotype or 
quantitative trait. Next, assume we have chosen two statistical tests for a region-
based association analysis: one genotype-based and one haplotype-based tests. 
For haplotype-based test haplotypes can be inferred from genotypes68; 69; 123 or 
assembled from sequencing data.71-73 Several conventional genotype-based 
methods are applicable for common variants testing.95; 128; 129 For sequencing data 
numerous recently-developed rare variants approaches are available.24; 35; 36; 56 
Haplotype-based methodologies have also been extensively published 
elsewhere,130-132 including rare haplotype tests.74-76   
The combined approaches 
Let us denote p-values from a genotype- and a haplotype-based tests as 𝑝1 and 𝑝2 
respectively. Our first approach is SumP-val.83 Let us consider the inverse 
standard normal transformation of both p-values 𝑦1 = Φ
−1(1 − 𝑝1) and 𝑦2 =
Φ−1(1 − p2), which are distributed as standard normal random variables under 
the null hypothesis. Here, we assume that (𝑦1, 𝑦2) is bivariate normal. SumP-val 
81 
 
test statistic is 𝑝𝑠𝑢𝑚 = 𝑦1 + 𝑦2. Under the null hypothesis, it is distributed as a 
normal random variable with zero mean and variance 𝑉𝑎𝑟(𝑦1 + 𝑦2) = 𝑉𝑎𝑟(𝑦1) +
2𝐶𝑜𝑣(𝑦1, 𝑦2) + 𝑉𝑎𝑟(𝑦2) = 2 + 2𝜌, where 𝜌 is a correlation coefficient between 
𝑦1 and 𝑦2, since two statistical tests for the same genomic region may not be 
independent. The correlation coefficient 𝜌 may be estimated via permutation 
procedure. The rejection region is large values of the test statistic, which is 
equivalent to low values for 𝑝1 and/or 𝑝2. Theoretical p-value for SumP-val test is 
calculated as 1 − Φ(𝑦1 + 𝑦2; 0, 2 + 2𝜌), where Φ(𝑎; 𝑏, 𝑐) is a value of normal 
cumulative distribution function with mean 𝑏 and variance 𝑐 taken at the point 𝑎.  
Our second approach (MinP-val) is to utilize the minimum of the two p-values as 
a test statistic, namely, 𝑚𝑖𝑛{𝑝1, 𝑝2}.
133 Let us represent a test statistic as 
𝑚𝑖𝑛{𝑝1, 𝑝2} = 𝑚𝑖𝑛{1 − Φ(𝑦1), 1 − Φ(𝑦2)}, where 𝑦1 and 𝑦2 defined above are 
distributed as standard normal random variables under the null hypothesis. Thus, 
the theoretical cumulative distribution function of MinP-val test statistic under the 
null hypothesis can be calculated as follows: 
𝑃(𝑚𝑖𝑛{1 − Φ(y1), 1 − Φ(y2)} < 𝑥) = 𝑃(1 − 𝑚𝑎𝑥{Φ(y1), Φ(y2)} < 𝑥) = 
= 𝑃((1 − 𝑥) < 𝑚𝑎𝑥 {Φ(𝑦1), Φ(𝑦2)}) = 1 − 𝑃(1 − 𝑥 > Φ(y1), 1 − x > Φ(y2) ) 
= 1 − 𝑃(Φ−1(1 − 𝑥) > y1, Φ
−1(1 − x) > y2 ), (28) 
where 0 < 𝑥 < 1. Given the rejection region is small values of the test statistic, 




 Theoretical power model 
Within our theoretical framework the following model is adopted: the two test 
statistics 𝑆𝑔 and 𝑆ℎ of the underlying genotype- and haplotype-based tests, 
respectively, are assumed to asymptotically follow central chi-squared 
distribution 𝜒1
2 with 1 degree of freedom under the null hypothesis, and non-
central chi-squared 𝜒1,𝑎
2  and 𝜒1,𝑏
2  with non-centrality parameters (NCPs) 𝑎 and 𝑏, 
respectively, under the alternative hypothesis. One example of a test with such 
null and alternative distributions is Rao’s score test on genotype or haplotype 
scores described in Appendix to Chapter 4. Since the two tests are applied to the 
same data, the chi-squared test statistics are likely to be positively correlated. The 
correlation between the two test statistics may vary from very low to high. For 
example, if within a region there are few SNPs in very high LD, then we would 
expect the correlation between the tests to be high. Alternatively, we would 
expect the correlation to be low when variants within a region are independent. 
The correlation is modeled via underlying multivariate normal distribution. 
Namely, to simulate the test statistics 𝑆𝑔~𝜒1,𝑎
2  and 𝑆ℎ~𝜒1,𝑏
2  a bivariate normal 
random vector 𝑦 = (𝑦1, 𝑦2) with mean (√𝑎, √𝑏), unit variances and correlation 
coefficient 𝜌 > 0 is generated, and the squares of the coordinates are taken as the 
proxy for the test statistics: 𝑆𝑔 = 𝑦1
2, 𝑆ℎ = 𝑦2
2. To estimate power of MinP-val 
and SumP-val tests we simulated 500,000 independent pairs (𝑆𝑔, 𝑆ℎ) under the 
alternative hypothesis, calculated the test statistics for the combined approaches, 
and noted the share of statistically significant pairs. This procedure was done for 
every theoretical scenario (see “Results” section). 
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Population genetics simulations 
King et al67 provided the SFS_CODE (http://sfscode.sourceforge.net) 
implementation of population genetics simulation for ANGPTL4 gene exons. The 
authors assumed the demographic and distribution fitness effect parameters from 
Boyko et al96 and Gutenkunst et al.97 Using the SFS_CODE program 1000 
haplotype pools each containing 20000 sampled “individuals” (40000 
chromosomes) from European population were generated. A data replicate was 
created from each haplotype pool by iterative random sampling of two haplotypes 
(thus, defining the genotype of an “individual”) and assigning a dichotomous 
phenotype conditional on a multi-site genotype or a pair of haplotypes. Each data 
replicate contains 500 cases and 500 controls. Let us assume that there are L 
variants within the genomic region of interest, and the genotype of “an 
individual” {𝑔1, … , 𝑔𝐿} is constructed from the sampled haplotypes. To describe 
the genotype-based disease model let us, without loss of generality, denote the 
genotypes at rare (MAF<1%) causal SNPs as {𝑔1, … , 𝑔𝑐}, causal common SNP 
𝑔𝑐+1 (if present depending on a model), and other SNPs as {𝑔𝑐+2, … , 𝑔𝐿}. Let us 
also define the assigned odds ratios of causal variants {𝑏1, … , 𝑏𝑐+1}. The 
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For the haplotype-based scenarios let us consider two sampled haplotypes 
{ℎ1, ℎ2}. Also, denote 𝐻𝑟 and 𝐻𝑐 as the sets of rare (frequency in a haplotype pool 
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<1%) and common causal haplotypes, respectively (depending on the disease 












where 𝐼{𝐴} is an indicator of an event 𝐴, and {𝑑𝑟 , 𝑑𝑐} are the odds ratios for 
causal rare and common haplotypes, respectively. For our simulations, we 
considered three phenotype models: “Rare” (only rare variants or haplotypes are 
risk-contributing), “Common” (only common variants or haplotypes), and “Both” 
(both types of variants or haplotypes). Following the scenarios of exome-scale 
simulations of Wu et al,41 we have assigned 50%, 20% and 10% of the observed 
rare variants (haplotypes) to be causal.  
Phenotype model 
Proportion of causal variants/haplotypes 
50% 20% 10% 
Haplotype common 32.4 31.6 31.6 
Haplotype both 35.5 33.2 32.6 
Haplotype rare 37.2 34.1 33.0 
Genotype common 33.1 32.4 32.2 
Genotype both 36.3 33.7 32.9 
Genotype rare 37.6 34.4 33.0 
Table 7: The average number of variants within a region across 1000 data replicates in 
population genetics simulations. Extracted from Zakharov et al.134 
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Additionally, we chose one common causal SNP (haplotype) for “Both” and 
“Common” models. The odds ratios {𝑏𝑙}𝑙=1
𝑐+1 in (29) and {𝑑𝑟 , 𝑑𝑐} in (30) were 
assigned as follows:  
 for the “Rare” model: 𝑏𝑙 = 𝑑𝑟 = 4, 𝑙 = 1, . . , 𝑐 and 𝑏𝑐+1 = 𝑑𝑐 = 0; 
 for the “Both” model: 𝑏𝑙 = 𝑑𝑟 = 3, 𝑙 = 1, . . , 𝑐 and 𝑏𝑐+1 = 𝑑𝑐 = 1.2; 
 for the “Common” model: 𝑏𝑙 = 𝑑𝑟 = 1.5, 𝑙 = 1, . . , 𝑐 and 𝑏𝑐+1 = 𝑑𝑐 = 2. 
The average number of variants across data replicates is shown in Table 7. 
Analysis of central corneal thickness GWAS data sets 
To demonstrate the performance of the described methodologies we conducted a 
gene-based analysis of the central corneal thickness (CCT) GWAS data sets 
described in Vithana et al.135 Briefly, the Singapore Indian Eye Study (SINDI), 
which is part of the Singapore Indian Chinese Cohort Eye Study (SICC),136 
consists of 2538 Indian subjects aged 40 and above, and the Singapore Malay Eye 
Study (SiMES)137-139 is a genome-wide association study of CCT phenotype 
which contains 2542 Malay subjects aged 40 and above. Both SiMES and SICC 
adhered to the Declaration of Helsinki. Ethics approval for the both studies was 
obtained from the Singapore Eye Research Institute Institutional Review Board.135 
The combined data set consists of 5080 individuals genotyped at 552318 SNPs 
after quality control. In total, 5049 individuals were analyzed after excluding 
those with missing phenotype. Also, we attempted to replicate all the genome-
wide significant regions using Chinese samples from the SICC. This data set 
contains 2837 samples with non-missing phenotype and covariates (age and 
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gender). SNPs were mapped to genes based on the method outlined by Zhao et 
al.140 Briefly, information on gene identifiers (IDs), names, start and end positions 
on a chromosome were downloaded from NCBI Genome database 
(http://www.ncbi.nlm.nih.gov/Genomes). Gene regions included 10 kb upstream 
and downstream. Hierarchical mapping scheme (coding>intronic>5’UTR> 
>3’UTR) was used if a variant was within 10 kb of multiple genes. The remaining 
inter-gene variants between two genes were grouped together. Haplotype 
inference was performed using Beagle68 with reference panel from 1000Genomes 
Project (http://www.1000genomes.org/). In our analysis we adjusted for age, 
gender and the first ten principal components from Eigenstrat.49  
Statistical tests for population genetics simulations and real data application 
Sequence Kernel Association Test (SKAT), introduced by Wu et al,41 is a 
variance component score test derived from a semi-parametric regression model. 
It was initially proposed to test an association of phenotype with multi-site 
genotype; however, we also used SKAT to test an association of phenotype with 
haplotypes as described below. To show the consistency of empirical results we 
applied the same pair of underlying tests, namely, genotype SKAT and haplotype 
SKAT with linear kernel and uniform weights, to both population genetics 
simulations and real data. For genotype SKAT all rare variants (MAF<1% in the 
sample) within a region were collapsed according to the method described by 
Thalamuthu et al.46 Briefly, the collapsed super-variant is the sum of minor alleles 
across rare variants within a region; if this sum is greater than 2 then the value of 
2 is assigned. We did not apply weighting as described by Wu et al41 because that 
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would substantially decrease power to identify an association with common 
SNPs. Haplotype-based SKAT is SKAT applied to a haplotype regression matrix 
𝑅, which is constructed similar to those used by Zaykin et al.132 First, we pooled 
all rare haplotypes into one haplotype group, whereas each of the common 
haplotypes formed a separate haplotype group. Let us define the following 
notations: 𝑛 is a number of individuals; {𝐻1, … , 𝐻𝑀} is the haplotype groups with 
𝐻𝑀 being the most common group; 𝑅 = {𝑅𝑖𝑗}𝑖,𝑗=1
𝑛,𝑀−1
 is a haplotype regression 
matrix; and {ℎ𝑖,1; ℎ𝑖,2} is a pair of haplotypes for 𝑖th individual. The haplotype 
matrix 𝑅 = {𝑅𝑖𝑗}𝑖,𝑗=1
𝑛,𝑀−1
 is constructed as follows: 
𝑅𝑖𝑗 = 𝐼{ℎ𝑖,1 ∈ 𝐻𝑗} +  𝐼{ℎ𝑖,2 ∈ 𝐻𝑗}, 𝑖 = 1, … , 𝑛;  𝑗 = 1, … , 𝑀 − 1, (31) 
where 𝐼{𝐴} is an indicator of an event 𝐴. If there were no common haplotypes 
within a region, we formed three groups of haplotype: those with a frequency less 
that 0.05%, those in between 0.05% and 0.1%, and those with a frequency greater 
than 0.1%. For both tests we used the R (http://www.r-project.org/) package 
SKAT (http://www.hsph.harvard.edu/~xlin/software.html). For population 
genetics simulations p-values for all the tests were estimated using 1000 
permutations. Given large sample size and normal distribution of CCT135, 
theoretical p-values of the underlying tests were used for GWAS analysis. Then 
we tested an assumption of bivariate normality by applying the Shapiro-Wilk test 
(R package “mvnormtest” http://cran.r-project.org/web/packages/mvnormtest). If 
the normality test was not significant on the genome-wide level, we used 
theoretical p-values for both SumP-val and MinP-val; otherwise we used 
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permutations. The permutation procedure and estimation of correlation coefficient 
𝜌 are described in the next subsection. 
Permutation procedure and estimation of correlation coefficient 
To calculate theoretical p-values for the proposed methods we estimated the 
correlation coefficient 𝜌 using 500 permutations. The difficulty in applying 
permutations lies in the fact that the permutation procedure should preserve the 
relationship between all the covariates, and also between phenotype and 
covariates, but disrupt the relationship between phenotype and genotype. Several 
techniques have been developed for conducting permutation tests of partial 
coefficients in a multiple regression model.141-143 Among them permutation of 
residuals under the reduced model142 was shown to preserve correct type-1 error 
for t-test144 and was previously applied to microarray data analysis.145 As SKAT 
test can be obtained from a semi-parametric regression model41, let us consider 
the following genotype and haplotype regression models: 𝑌 = 𝑎1 + 𝑓1(𝑃) + 𝐶𝑐 +
𝜀 and 𝑌 = 𝑎2 + 𝑓2(𝑅) + 𝐶𝑐 + 𝜀, where 𝑃 is 𝑛 × 𝐿 collapsed genotype matrix, 𝑛 is 
the sample size, 𝐿 is the number of common SNPs within a region plus one for 
collapsed rare variants super-locus, 𝑌 is 𝑛 × 1 vector of quantitative phenotype 
(CCT), 𝐶 is 𝑛 × 12 matrix of covariates which include age, gender and the first 
ten genotype principal components obtained from Eigenstrat,49 𝑅 is haplotype 
regression matrix, and 𝑓1 and 𝑓2 are unknown functions. To obtain permutation 
values for the test statistics the reduced model 𝑌 = 𝑎 + 𝐶𝑐 + 𝜀 is fitted. Let 
𝑎′, 𝑐 ′, 𝜀′ be the estimated constant coefficient, regression coefficients and 
residuals, respectively. Next, the residuals 𝜀′ are permuted to obtain 𝜀∗, and 
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phenotype is reconstructed 𝑌∗ = 𝑎′ + 𝐶𝑐 ′ + 𝜀∗. Permuted statistic values for both 
genotype and haplotype SKAT tests are calculated as respective SKAT statistics 
from semi-parametric models 𝑌∗ = 𝑎1 + 𝑓1(𝑃) + 𝐶𝑐 + 𝜀 and 𝑌
∗ = 𝑎2 + 𝑓2(𝑅) +
𝐶𝑐 + 𝜀. Each p-value obtained from permutations was transformed using the 
inverse standard normal transformation. The value of  𝜌 was estimated by a 
Pearson correlation coefficient. 
Results 
Theoretical power results 
Depending on disease model, one of the underlying tests (genotype- or haplotype-
based) is expected to be more powerful than the other underlying test. So, we 
assume that under the alternative hypothesis the non-centrality parameter (NCP) 
of the more powerful underlying test is 𝑎, and the NCP of the less powerful 
underlying test is 𝑏 = 𝑎/2. Figures 20 and 21 (Panel 1) show the power of MinP-
val and SumP-val strategies as a function of correlation coefficient 𝜌 and NCP 𝑎 
at the fixed type-1 error rate of 0.05. As can be seen in Panel 1, power in general 
decreases slightly with increasing correlation. Panel 2 depicts the difference in 
power between the combined approaches and the more powerful underlying test. 
It is notable that both MinP-val and SumP-val achieved greater power than the 
more powerful underlying test for lower correlation. Also, MinP-val approach lost 
a maximum of 5% power for high correlation and gained a maximum of 2% for 





Figure 20: Performance of MinP-val approach under the theoretical models. Adapted from 
Zakharov et al.134 
Different lines across the panels correspond to different levels of correlation 𝜌 - 0, 0.3, 0.6 and 0.9. 
Panel 1: Power of MinP-val test as a function of NCP 𝑎 and correlation 𝜌; Panel 2: Difference in 
power between MinP-val and the more powerful underlying test as a function of NCP 𝑎 and 
correlation 𝜌; Panel 3: Difference in power between MinP-val and the less powerful underlying 
test as a function of NCP 𝑎 and correlation 𝜌; Panel 4: Power of MinP-val test as a function of 
correlation 𝜌 and the ratio of NCP 𝑏 to NCP of the more powerful underlying test (the latter is 









Figure 21: The performance of SumP-val approach under the theoretical models. Adapted 
from Zakharov et al.134 
Different lines across the panels correspond to different levels of correlation 𝜌 - 0, 0.3, 0.6 and 0.9. 
Panel 1: Power of SumP-val test as a function of NCP 𝑎 and correlation 𝜌; Panel 2: Difference in 
power between SumP-val and the more powerful underlying test as a function of NCP 𝑎 and 
correlation 𝜌; Panel 3: Difference in power between SumP-val and the less powerful underlying 
test as a function of NCP 𝑎 and correlation 𝜌; Panel 4: Power of SumP-val test as a function of 
correlation 𝜌 and the ratio of NCP 𝑏 to NCP of the more powerful underlying test (the latter is 





In Panel 3, where the difference in power between the combined approaches and 
the less powerful underlying test is shown, it can be seen that both MinP-val and 
SumP-val are consistently better than the less powerful test. This suggests that 
combination of statistical tests may prove beneficial when the underlying disease 
model is unknown. To investigate the impact of change of NCP 𝑏 on the 
performance of the proposed approaches we fixed NCP 𝑎 to be equal to 10.5 
(corresponding to 90% power of a chi-squared test with 𝜒1,𝑎
2  distribution under the 
alternative hypothesis, the type-1 error rate is 0.05). Panel 4 of Figures 20 and 21 
depicts the power of MinP-val and SumP-val as a function of correlation and a 
“fraction of NCP” – the ratio of 𝑏 to 10.5. As can be seen in Panel 4, MinP-val 
test achieved higher power than SumP-val in the majority of scenarios. It is 
notable that SumP-val lost much power when the value of 𝑏 is low. Hence, MinP-
val approach is more robust with respect to underperformance of one of the 
underlying tests. 
Population genetics simulation results 
Panel 4 of Figure 22 shows the empirical type-1 error estimate for the theoretical 
level of 0.05 for all the tests. The estimate of type-1 error is distributed as a 
binomial random variable with 1000 trials and the probability of success 0.05 
under the hypothesis of no inflation. The one-sided 99% quantile of the described 
distribution is 0.067. As can be seen, in our simulations the type-1 error was well 
controlled for all the tests. 
Panles 1-3 of Figure 22 depict the results of population genetics simulations 
analysis for all the phenotype models with 50%, 20% and 10% of rare causal 
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variants/haplotypes, respectively, at the fixed 5% type-1 error. For all the tests 
1000 permutations were performed to estimate p-values. Haplotypes were 
assumed to be known without ambiguity. Under the genotype-based disease 
scenarios, genotype SKAT is expected to be more powerful than haplotype 
SKAT, and vice versa under the haplotype-based scenarios. However, genotype 
SKAT was less powerful for many genotype-based models. A possible 
explanation of this observation is that when rare variants are strongly associated 
with phenotype for some statistical tests pooling of rare haplotypes may be a 
better strategy than pooling of rare variants.  
Also, it should be noted that with the decrease in the percentage of causal rare 
variants/haplotypes, the power for “Rare” and “Both” phenotype models decrease 
substantially since for these models rare variants/haplotypes are the major carriers 
of an association signal. For “Common” phenotype model one common 
variant/haplotype has a significant impact on phenotype; so, the decrease in power 
with the lower proportion of causal rare variants/haplotypes is not as high as for 
other phenotype models. 
As can be seen from the Panels 1-3 of Figure 22, for all the phenotype disease 
models when both underlying tests were almost equally powerful (e.g. Panel 1 
haplotype disease scenario “Common” model, and genotype disease scenario 
“Both” and “Common” models), the power of both MinP-val and SumP-val were 
on the same level or even higher than those of the underlying tests. However, 
when genotype-based SKAT significantly underperformed haplotype-based 










Figure 22: Power comparison of genotype-based SKAT, haplotype-based SKAT, MinP-val 
and SumP-val tests for population genetics simulations, and an estimate of empirical type-1 
error. Extracted from Zakharov et al.134 
In each panel the top three disease models correspond to the haplotype-based disease scenario, 
whereas the lower three correspond to the genotype-based scenario. Disease models “Rare”, 
“Both” and “Common” are described in the section “Population genetics simulation”. Type-1 error 
is set to 5%. Panel 1: 50% of rare variants/haplotypes were assumed to be causal; Panel 2:  20% of 
rare variants/haplotypes were assumed to be causal; Panel 3:  10% of rare variants/haplotypes 
were assumed to be causal; Panel 4:  empirical type-1 error estimate for simulations under the null 
hypothesis. 
 
MinP-val approach showed slightly lower power than the more powerful 
underlying test and greater power compared with SumP-val approach. The 
maximum power loss of SumP-val and MinP-val compared with the more 
powerful underlying test across all phenotype models was 6.3% and 3.8% 
respectively (haplotype disease scenario “Both” model). These results are 
consistent with those obtained from the theoretical power considerations and 
illustrate the great potential of the proposed methods in their application to real 
association studies. To examine the effect of phasing on our results we repeated 
the analysis using the most probable haplotypes inferred by Beagle.68 The 
reference panel consisted of 1094 simulated individuals to mimic the size of the 
publicly available reference panel from the 1000 Genomes Project 
(www.1000genomes.org). The results of this analysis were very similar to those 
described above (data not shown). In addition, we applied the proposed methods 
with a different pair of underlying tests. The results are similar to those described 
above. For more details, see Appendix to Chapter 4. 
Application to GWAS of central corneal thickness  
A total of 552318 SNPs were mapped using the hierarchical mapping algorithm 
described in the “Methods” section. As a result, we obtained 36146 genes and 
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between-gene blocks. Regions that reached genome-wide significance (1.38E-6 
after Bonferroni correction) for at least one of the four applied tests are presented 
in Table 8. We identified all the significant regions reported by Vithana et al135: 
COL8A2 gene, an interval between genes RXRA and COL5A1 and a region near 
ZNF469 gene. As can be seen from Table 8, genotype-based SKAT and MinP-val 
tests achieved genome-wide significance for all the five regions listed, whereas 
SumP-val failed to reach genome-wide significance for both RXRA-COL5A1 and 
C7orf42 regions. This highlights that MinP-val approach performed better than 
SumP-val. Haplotype-based SKAT failed to identify any association signal for 
four out of the five regions. From our results it is clear that for this data set 
genotypes were more relevant for identifying associated regions. Judging from the 
performance of Haplotype SKAT there is no evidence of association of 
haplotypes with a phenotype except for COL8A2 gene. It is also of interest to 
compare our results to those reported by Vithana et al135 for single-SNP analysis. 
For the two out of three regions genotype-based SKAT and MinP-val methods 
outperformed single-SNP analysis and yielded lower p-values, which may be 
explained by the utilization of linkage disequilibrium (LD) within a region to 
boost power. Given the sensitivity of SumP-val approach to underperformance of 
one of the underlying tests, this method showed higher p-values relative to single-
SNP analysis. To justify our assumption of bivariate normality for calculation of 
p-values for the proposed methods, we used Shapiro-Wilk test. The corresponding 
p-values for the significant regions are presented in Table 9 in the first row. All p-













Chromosome 1 16 9 1 7 
Number of 
SNPs 
4 27 73 3 6 
Genotype 
SKAT 
3.7E-13 2.1E-15 4E-12 2.6E-08 2.6E-07 
Haplotype 
SKAT 
5.6E-10 0.15 0.79 2.78E-05 0.005 
MinP-val 3.7E-13 4.2E-15 8.1E-12 4E-08 5E-07 












Table 8: The results of the combined SiMES and SINDI data analysis and the single-SNP p-
values from the original article. Extracted from Zakharov et al.134 
Genome-wide significant p-values for gene-based tests are shown underlined. * SiMES and SINDI 




















SiMES+SINDI 0.08 0.07 0.73 1.4E-6 0.04 
Replication 
dataset 
0.23 0.15 0.23 3E-3 0.43 
Table 9: P-values for the Shapiro-Wilk bivariate normality test for genome-wide significant 













0.019 0.117 0.001 1 0.014 
Haplotype 
SKAT 
0.599 0.479 0.1 1 0.27 
MinP-val 0.037 0.223 0.002 0.989 0.028 












Table 10: Replication results on Chinese samples from the Singapore Indian Chinese Cohort 
Eye Study. Extracted from Zakharov et al.134 
Significant p-values are shown underlined. For single-SNP analysis the Bonferroni correction 
corresponds to the four tests. * Trend test within a linear regression model. 
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genome-wide level, which suggests there is no evidence against the bivariate 
normality assumption. Since Shapiro-Wilk test of COL8A2-TRAPPC3 region 
yielded a marginally significant p-value on the genome-wide level, p-value for 
this region in Table 8 is based on permutations.  
Table 10 shows the results of the replication analysis. For the region COL8A2-
TRAPPC3 the reported replication p-value is based on permutations, whereas for 
other regions there was no evidence against bivariate normality assumption (Table 
9, second row). As can be seen from Table 10, only RXRA-COL5A1 region was 
significant after Bonferroni correction for all the tests except for the haplotype-
based SKAT. Our replication results are consistent with those of Cornes et al146 
who found strong evidence of association of multiple SNPs within the RXRA-
COL5A1 region, and marginal significance of COL8A2 SNP rs96067. It is worth 
noting that in our analysis C7orf42 gene, which was not identified by Vithana et 
al135, reached genome-wide significance in SiMES+SINDI data set and had 
moderate p-value in the replication dataset. Cornes et al146 found this gene to be 
significant in a meta-analysis of SiMES, SINDI, 1883 samples from the 
Singapore Chinese Eye Study and 798 samples from the Beijing Eye Study.147 
The role of C7orf42 gene in central corneal thickness (CCT) phenotype requires 
further investigation. The results of our analysis suggest that RXRA-COL5A1 
region may have an impact on CCT phenotype. 
In addition to the gene-based analysis, we tried to replicate the four genome-wide 
significant SNPs found by Vithana et al135 in our Chinese samples using single-
SNP analysis. Having tested an association of these SNPs with CCT trait using 
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trend test within a linear additive model adjusting for age, gender and the first ten 
principal components, we found that none of the SNPs was significant on the 
corrected type-1 error rate 0.0125 = 0.05/4. This result suggests that gene-based 
replication may be a more powerful strategy than single-SNP replication.  
In addition to the main genome-wide analysis of SiMES+SINDI data set, we 
applied the proposed methods with a different pair of underlying tests to the three 
regions reported by Vithana et al135. Both MinP-val and SumP-val identified the 
three regions on genome-wide significance level. This result suggests that our 
combined approaches work as well with other underlying tests (for more details, 
see Appendix to Chapter 4). 
Discussion 
When the underlying disease model is unknown, combining statistical tests 
tailored for different disease scenarios may be a better strategy than application of 
a statistical test designed for one specific disease model. In this chapter we have 
described two approaches of combining genotype- and haplotype-based statistical 
tests. The results of theoretical power simulations, population genetics 
simulations and real data analysis showed strong performance of MinP-val 
approach for different disease scenarios. Our analysis of SiMES+SINDI identified 
the three regions found by Vithana et al135, and additionally, the C7orf42 gene. 
The replication analysis confirmed an association of RXRA-COL5A1 region, 
which is consistent with the results of Cornes et al146, and showed a moderate p-
value for C7orf42 gene. The analysis of real data highlighted the applicability of 
our combined approaches to real association studies.  
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In our simulations Haplotype SKAT was the most powerful test in many cases, 
but in real data analysis it performed the worst. It is not known beforehand 
whether a genotype- or a haplotype-based test would perform better; hence, our 
proposal to apply a combined approach is a robust choice. Indeed, MinP-val did 
well in both simulations and real data. This emphasizes the major point of the 
combined strategy: MinP-val may have slightly lower power when a disease 
model fits Haplotype SKAT and higher power when the disease model is closer to 
the second underlying tests. One of the possible reasons for the apparent 
inconsistency of Haplotype SKAT performance may be that for “Rare” and 
“Both” simulation models we assumed that rare variants bear the major 
association signal whereas in the real data only common SNPs were present. 
However, Haplotype SKAT performed well even for “Common” model when a 
common SNP was causal. We suppose that for this scenario genotype association 
translated into an association of haplotypes with a phenotype, which is possible if 
common SNPs within a region are in high LD with each other. On the other hand, 
if a causal common SNP within a region is in low LD with other common SNPs 
within a region, then haplotype-based test may have much lower power than a 
genotype-based test, which is observed in the results of the real data analysis.  
The methods proposed in this study may be easily generalized to multiple 
statistical tests, namely, instead of two underlying tests it is possible to apply 
more tests and combine all of them via the described methodology. In this case 
the arguments for theoretical p-value calculation for the proposed approaches can 
be extended in a straightforward manner. Also, the described methodologies may 
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be extended to preserve power under other disease models. For example, the 
combination of rare-variants and common-variants statistical tests applied to a 
sequenced region may preserve high power when either only rare or only common 
variants are associated with a phenotype. However, it is not known how the 
combined approaches will perform if both common and rare variants are 
associated with phenotype. 
Recently Derkach et al148 investigated the performance of the combined 
approaches, namely, the minimum of p-values and the Fisher p-value 
combination, for rare variants association scenarios. Although the approaches we 
propose are similar, our major idea is different. We combine two test statistics for 
the purpose of widening the set of alternatives for which our test is powerful; 
thus, we choose the underlying tests designed for very different phenotype 
models, whereas Derkach et al148 used linear and quadratic tests which are likely 
to be both powerful under many models. As a result, our conclusions are different 
from those of Derkach et al148. For example, the authors stated that “hybrid test 
statistics provide much needed robustness in terms of power for association tests”, 
whereas we observed that only minimum p-value approach really preserves power 
when one of the underlying tests underperforms. Secondly, the authors found that 
in many cases Fisher method outperforms both of the underlying tests, and the 
minimum p-value approach. However, from our work it is clear that SumP-val 
(which is similar to the Fisher p-value combination) outperforms all the three tests 
only when both of the underlying tests have comparable power, which is unlikely 
if underlying tests are deliberately chosen to fit very different phenotype models.  
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One of the limitations of the proposed approaches is the need to use permutations. 
For theoretical p-value calculation both SumP-val and MinP-val require a 
correlation coefficient 𝜌 to be estimated via permutations. Moreover, 
permutations need to be applied when asymptotic distributions of the underlying 
test statistics are unknown or inadequate to describe the empirical distributions.  
Conclusions 
In this study we have investigated the performance of combined haplotype- and 
genotype-based tests for the purpose of preserving high power under both 
genotype and haplotype disease scenarios. Based on theoretical power 
simulations, population genetics simulations and analysis of the real data set we 
have illustrated high performance and potential utility of combined approaches for 









Chapter 5 – Improving power for robust trans-ethnic meta-
analysis of rare and low-frequency variants with a partitioning 
approach 
Background 
Meta-analysis of genome-wide association studies (GWAS) have identified 
hundreds of common genetic variants associated with complex diseases.4; 82 
Indeed, meta-analysis of multiple datasets improves the chance of discovering 
associated variants with moderate or low effect size which were missed in 
individual studies due to insufficient power at a stringent genome-wide 
significance level. Given the development of next-generation sequencing 
technologies149 and the fact that for many traits the discovered common genetic 
variants explain only a small proportion of variability attributable to genetic 
factors3, researchers have recently devoted much attention to rare variants which 
may hold a clue to the problem of missing heritability. Indeed, evidence that rare 
variants are associated with complex traits are starting to emerge.18; 21; 89  Given 
the potential of whole-exome and whole-genome sequencing studies to become as 
commonplace as genome-wide association studies (GWAS) today, it is natural to 
foresee meta-analysis methods to be applied for the identification of rare variants 
with moderately larger effect sizes. 
Meta-analyses of studies across different populations and ethnic groups have the 
potential to improve the statistical power to identify rare variants association by 
increasing the number of samples in the joint analyses.150 However, when doing 
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trans-ethnic meta-analysis, one faces the problem of effect size heterogeneity, 
defined as a difference in the effect size across studies, which may stem from: (i) 
differences in study design (e.g. in the definition of the phenotype); (ii) varying 
impact of genetic variants due to interaction with other variants found at different 
frequencies across populations; and (iii) different environmental and lifestyle 
factors. In addition, the analysis of rare variants typically adopts a region-based 
approach to evaluate the joint genetic burden from multiple variants, given that 
single-variant statistical methods tend to be underpowered because of stringent 
multiple testing correction and low allele frequency of individual rare variants. 
Thus, one also faces the problem of allelic heterogeneity within a region as rare 
variants are more likely to be population-specific.151; 152 Given these challenges it 
is important to develop powerful methodologies for trans-ethnic rare variant meta-
analysis which will perform well in the presence of both effect size heterogeneity 
and allelic heterogeneity. 
In this chapter, we introduce a method for performing a region-based trans-ethnic 
meta-analysis of rare variants that is centered on identifying appropriate partitions 
of the input data. The method aims to cluster the input studies based on a 
population genetics argument, before proceeding to measure the association 
evidence within each cluster. The within-cluster evidence is subsequently 
combined across clusters to yield a single measurement of statistical evidence of 
phenotype association for each genomic region. Our method is compared against 
conventional meta-analysis methodologies, such as those by Fisher and Stouffer, 
and two of the recently proposed rare-variant meta-analysis methods 
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(MetaSKAT87 and MV SKAT88) with a series of simulations which assumed 
different extent of heterogeneity between ancestry groups. The results from our 
simulations indicated that our method was either comparable or outperformed 
existing methodologies for performing trans-ethnic rare-variant meta-analyses.  
Methods 
Apcluster meta-analysis 
Let us assume we have 𝑛 study groups in a meta-analysis with group-level p-
values 𝑝1, … , 𝑝𝑛 for a genomic region of interest (p-values are obtained using 
some region-based rare variants association test). Let us define the study group 










where 𝑆𝑖 is the set of all variants (both common and rare) observed in the 𝑖
th study 
group, and the operator # maps a set to a number of elements in this set. The 
numerator thus measures the number of variants that are jointly present in both 
study 𝑖 and study 𝑗, while the denominator measures the number of variants that at 
least in one of study 𝑖 or study 𝑗. The similarity measure thus varies between 0 
and 1. The intuition behind this similarity measure is based on the population 
genetics assumption that the shorter the time to the most recent common ancestor 
(TMRCA) between two populations, the greater the proportion of variants they 
will share than compared to those populations with a longer TMRCA.  
Next, the study groups are partitioned with the use of an affinity propagation 
clustering algorithm.153 Let 𝑠𝑖𝑗 denote the similarity measure between the 𝑖th and 
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𝑗th study groups, subsequently known as the 𝑖th and 𝑗th nodes. The affinity 
propagation algorithm considers 𝑠𝑖𝑗 as a measure of how well the 𝑗th node is 
suited to be an exemplar for the 𝑖th node (the exemplar is defined as the center of 
a cluster). A priori, all nodes are equally likely to be exemplars. Two kinds of 
messages are passed between the nodes, namely:  
 The responsibility 𝑟𝑖𝑗 is sent from the 𝑖th node to a candidate 𝑗th node, 
reflecting the evidence for how well the 𝑗th node is as an exemplar for the 
𝑖th node over all other exemplars;  
 The availability 𝑎𝑖𝑗 is sent from the 𝑗th node to the 𝑖th node, measuring 
how appropriate the 𝑗th node is chosen by the 𝑖th node as an exemplar, 
relative to the support from other nodes that the 𝑗th node is already an 
exemplar for.  
The initial values of all 𝑎𝑖𝑗 are set to 0, and the algorithm proceeds recursively 
between the following two updates:  
 Update 𝑟𝑖𝑗 = 𝑠𝑖𝑗 − max
𝑗′≠𝑗
{𝑎𝑗𝑗′ + 𝑠𝑗𝑗′}; 
 Update 𝑎𝑖𝑗 = 𝑚𝑖𝑛{0, 𝑟𝑗𝑗 + ∑ 𝑚𝑎𝑥{0, 𝑟𝑖′𝑗}𝑖′∉{𝑖,𝑗} } when 𝑖 ≠ 𝑗, and 𝑎𝑗𝑗 =
∑ 𝑚𝑎𝑥{0, 𝑟𝑗′𝑗}𝑗′≠𝑗 . 
At each iteration, the algorithm identifies the 𝑗th node as an exemplar for the 𝑖th  
node if 𝑎𝑖𝑗 + 𝑟𝑖𝑗 is maximized, except when the maximum is attained when 𝑗 = 𝑖, 
in which case the 𝑖th  node itself becomes the exemplar. We utilized the algorithm 
implemented in the R package “APcluster” (http://cran.r-project.org/web/ 
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packages/apcluster/index.html), where by default the algorithm terminates if the 
exemplars have not changed after 100 consecutive iterations, or when the 
exemplars have not converged after 1,000 iterations. When the latter occurs in our 
implementation, we assume a single cluster containing all the nodes, equivalent to 
applying the Fisher method to all the studies without partitioning. 
Let us denote the obtained clusters of study groups 𝐶1, … , 𝐶𝐾. The test statistic is 
obtained with the following: 





where the corresponding p-value ?̂?𝑘 can be calculated from a chi-square 
distribution at 2|𝐶𝑘| degrees of freedom;   
 Combine the p-values ?̂?𝑘 across all 𝐾 clusters using another round of 
Fisher meta-analysis: 
𝑇 = ∑ −2log (?̂?𝑘)
𝐾
𝑘=1 , (34) 
which under the null hypothesis is distributed as a chi-squared random variable 
with 2𝐾 degrees of freedom. This step assumes that the constituent studies within 




Other methodologies for performing rare variant meta-analyses 
We compared our rare variant meta-analysis setup (Apcluster) with some of the 
existing approaches: (i) two p-value based approaches were considered, namely 
the conventional Fisher combination and the Stouffer inverse standard normal 
transform method.83 These two approaches relied on the statistical evidence from 
two underlying group-level tests: SKAT41 with the linear kernel and the default 
beta weights in the R package “SKAT”, and a burden test which is a likelihood 
ratio test of a regression coefficient for a collapsed score defined as a number of 
rare minor alleles within a region of interest carried by an individual; (ii) Hom-
Meta-SKAT and Het-Meta-SKAT by Lee et al87 for meta-analyzing output from 
SKAT across studies from homogeneous and heterogeneous ancestry groups 
respectively, where the R implementation of these methods is available in a 
package “MetaSKAT” and the specific function “MetaSKAT_wZ” was used 
since we assumed the availability of individual-level data; (iii) the MV SKAT 
method recently introduced by Hu et al88, where we only considered the MV 
method but not the other two approaches (SV-I and SV-E) as these latter methods 
use additional reference data which would potentially make the comparison of the 
methods unfair. The authors of MV SKAT also indicated that the MV method 
performs the best and the performance of the two other approaches (SV-I, SV-E) 
closely resembled that of MV88. We implemented MV SKAT in R since there was 
no readily available source code by the authors of MV SKAT.  
Population genetics simulations for calculating power and false positive rates 
To estimate the type 1 error and power associated with the different methods for 
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performing rare variant meta-analyses, we performed a series of population 
genetics simulations with the coalescent simulator cosi assuming the best-fit 
population history model.154 Specifically, we generated 12 haplotype pools each 
containing 10,000 chromosomes across a 1Mb region, where four of the 
haplotype pools were generated by random sampling from a background 
assuming European ancestry, four assuming East Asian ancestry and four 
assuming African ancestry. We considered two classes of scenarios, 
corresponding to the “non-admixed” and “admixed” classes (Table 11). In the 
scenarios under the “non-admixed” class, the 12 studies in the meta-analysis 
corresponded to data generated from the 12 haplotype pools (four African studies 
Af1, Af2, Af3, Af4; four East Asian studies denoted EA1, EA2, EA3, EA4; and 
four European studies denoted E1, E2, E3, E4). In the scenarios under the 
“admixed” class, we generated data for seven studies with different degree of 
admixture, with three single-ancestry studies conducted assuming Africa (Af), 
East Asian (EA) and European (E) ancestry respectively, and four studies in 
admixed populations across the four possible ways of admixture: African and East 
Asian (Af-EA), African and European (Af-E), East Asian and European (EA-E), 
and across all three ancestry groups (Af-EA-E). Haplotype pools for the two-
ancestry admixed populations were generated by mixing the haplotypes from the 
respective populations with an admixture proportion which is drawn 
independently for each data replicate from a Uniform(0.2, 0.8) distribution. To 
generate the admixture proportions for Af-EA-E, we sampled a random vector 












N12 Non-admixed Af1-Af4, EA1-EA4, E1-E4 All 
N8 Non-admixed Af1-Af4, EA1-EA4, E1-E4 
EA1-EA4, 
E1-E4 
N4 Non-admixed Af1-Af4, EA1-EA4, E1-E4 E1-E4 
N8C Non-admixed Af1-Af4, EA1-EA4, E1-E4 
Af1-Af2, EA1-
EA3, E1-E3 
N4C Non-admixed Af1-Af4, EA1-EA4, E1-E4 
Af1, EA1, E1, 
E2 
A7 Admixed 




Af, EA, E, Af-EA, Af-E, 
EA-E, Af-EA-E 
E, Af-E, EA-E, 
Af-EA-E 
A2 Admixed 
Af, EA, E, Af-EA, Af-E, 
EA-E, Af-EA-E 
EA, E 
Table 11: Scenarios considered in population genetics simulations. Extracted from Zakharov 
et al.155 
1 Under the Non-admixed case, all studies were simulated uniquely from one ancestry group 
without admixture; whereas under the Admixed case, three studies were simulated uniquely from 
one ancestry group without admixture, and the remaining four studies were simulated considering 
all possible ways of admixture between three ancestry groups. 
2 Indicative of the ancestry group which the study was simulated in, consisting of African (Af), 
East Asian (EA) and European (E). Study symbols with hyphens indicate the ancestries 
contributing to the admixture, where Af-EA indicates a study simulated with admixed samples of 





algorithm presented in Onn and Weissman.156 Following Wu et al41, we simulated 
1000 data replicates of 30kb region each under the assumption of: (i) the null 
hypothesis of no association with a quantitative phenotype to calculate the false 
positive rate; and (ii) the alternative hypothesis where the region carried variants 
that are functionally associated with the phenotype to calculate power.  
To calculate power, we randomly chose 5% of the L rare variants (each with 
observed minor allele frequency  1%) that existed within the corresponding 
haplotype pool in each study to be causal. Note that this meant different rare 
variants may be selected to be causal in the different studies, thus our simulation 
setup naturally model the situation of allelic heterogeneity. For the purpose of 
presentation, let us enumerate the causal variants for a study population by the 
index range 1 ≤ 𝑙 ≤ 𝐿′ (with 𝐿′ = 𝑟𝑜𝑢𝑛𝑑[0.05𝐿]) and other rare non-causal 
variants by 𝐿′ + 1 ≤ 𝑙 ≤ 𝐿. We randomly sampled 2,000 chromosomes from the 
respective haplotype pool to form the genotype data for 1000 individuals, and 
generated a quantitative trait 𝑦𝑖 for the 𝑖th individual as 𝑦𝑖 = ∑ 𝑏𝑙𝑔𝑖𝑙
𝐿′
𝑙=1 + 𝑒𝑖 with 
𝑖 = 1, … ,1000, 𝑏𝑙 and 𝑔𝑖𝑙 are the effect size and minor allele count at the 
genotype for the 𝑖th individual at the 𝑙th causal variant (for 𝑙 = 1, … , 𝐿′) 
respectively, and 𝑒𝑖 follows a standard normal distribution. Following Wu et al
41, 
we assigned 𝑏𝑙 = 0.4| log10 𝑀𝐴𝐹𝑙 |, where 𝑀𝐴𝐹𝑙 is a minor allele frequency of 
the 𝑙th causal variant calculated from a respective haplotype pool. To simulate the 
quantitative trait under the null model of no association 𝑦𝑖 is simply obtained by 
sampling from a standard normal distribution.   
113 
 
Across the two classes that assumed no admixture and admixed populations 
respectively, we considered different scenarios of effect size heterogeneity (Table 
11). Under the class of “non-admixed” populations, we considered five scenarios 
where the simulated genomic region is associated: (1) in all twelve studies (N12); 
(2) only in the non-African studies (N8); (3) only in the European studies (N4); 
(4) in two African, three East Asian and three European studies (compound 
heterogeneity, abbreviated N8C); and (5) in on African, one East Asian and two 
European studies (N4C). Under the class of “admixed” populations, we 
considered three scenarios where the simulated region is associated: (1) in all the 
seven studies (A7); (2) only in the studies with at least some European ancestry 
(A4); and (3) only in the two populations (A2).  
The power is estimated from the 1000 data replicates in each scenario as the 
proportion of data replicates with meta-analysis p-value < 10-6. To model the false 
positive rate when the significance threshold was kept at 10-6, we adopted the 
procedure described in Lee et al87 to avoid the computationally intensive manner 
of performing at least 107 iterations: we simulated 2,000 genomic regions under 
each scenario but simulated 10,000 phenotype replicates under the null model for 
each genomic region. This approach provided 2 × 107 p-values to estimate the 
empirical Type 1 error associated with a significant threshold of 10-6.  
For p-value based methods the two group-level tests (SKAT and burden test) were 
applied to variants with MAF ≤ 1% in a data replicate. For Hom-Meta-SKAT and 
Het-Meta-SKAT, if a variant was rare in one population but not rare (MAF > 1%) 
in another population group, we treated this variant as missing for all the study 
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groups for which it was found to be not rare. This procedure ensured a fair 
comparison between the p-value based meta-analysis methods and those 
developed by Lee et al87. 
Theoretical power simulations assuming non-central Chi-squared 
distributions 
In addition to population genetics simulations, we considered a theoretical model 
to evaluate the performance of the Apcluster approach for combining p-values 
against the Fisher approach. We first assumed that, without loss of generality, the 
test statistic for each study under the null hypothesis was distributed as a Chi-
squared distribution with 1 degree of freedom (df), whereas under the alternative 
hypothesis, the test statistic followed a non-central Chi-squared distribution with a 
non-centrality parameter. Instead of simulating genetic and phenotypic data, we 
can simulate the resultant test statistics of the association analyses directly from 
the distributions under the null and alternative hypotheses according to the eight 
simulation scenarios that we assumed for the non-admixed and admixed classes 
(Table 11). For example, under the N8 scenario, eight test statistics will be drawn 
from a non-central Chi-squared distribution with a non-centrality parameter 
while the remaining four test statistics will be drawn from 𝜒1
2 distribution. The p-
values corresponding to these test statistics are obtained after mapping against the 
quantiles of 𝜒1
2 distribution. The power of the Fisher and Apcluster methods is 
derived as the proportion of 5,000 iterations where the meta-analysis p-value is 
more significant than 10-6. For the Apcluster partitioning, we combined the p-
values by mimicking the study partitionings which were most often observed in 
115 
 
our population genetics simulations in the respective scenarios (Table 12) – in the 
non-admixed case, the African, East Asian and European studies were always 
clustered by ancestry and thus we partitioned our test statistics accordingly; in the 
admixed case, we selected the two most common partitionings to consider in our 
theoretical considerations, denoted as P1 and P2 (Table 13).   
APcluster method website 
The R functions for the Apcluster method is packaged together with a sample 
dataset and accompanying codes for performing the association analysis. The 
simulated datasets for comparing power and the R package can be downloaded 
from http://www.statgen.nus.edu.sg/~software/apcluster.html. 
Results 
Type 1 error rates 
We evaluated the false positive rate of our approach (Apcluster) for combining p-
values against two classical strategies: (i) the Fisher method; and (ii) the Stouffer  
inverse-normal method, with 20,000,000 simulations under the null hypothesis of 
no association. At a significance threshold of 10-6, we observed that the empirical 
false positive rates of the Apcluster approach when applied to the output of SKAT 
ranged between 4.5 × 10-7 and 5.5 × 10-7 for the two classes of simulations that 
assumed 12 populations without admixture and 7 populations with some 
admixture respectively (Table 14). These figures were comparable to those 
obtained by the Fisher method (3.0 × 10-7, 6.5 × 10-7) and by the Stouffer method 








N12 (Af1-Af4), (EA1-EA4), (E1-E4) 100 
N8 (Af1-Af4), (EA1-EA4), (E1-E4) 100 
N4 (Af1-Af4), (EA1-EA4), (E1-E4) 100 
N8a (Af1-Af4), (EA1-EA4), (E1-E4) 100 
N4a (Af1-Af4), (EA1-EA4), (E1-E4) 100 
A7 
(EA, E, EA-E); (Af, Af-EA, Af-E, Af-EA-E) 30.6 
(EA); (E, EA-E); (Af, Af-EA, Af-E, Af-EA-E) 12.5 
(E); (EA, EA-E); (Af, Af-EA, Af-E, Af-EA-E) 6.7 
(Af-EA, EA, EA-E); (Af, E, Af-E, Af-EA-E) 6.5 
(E, EA-E, Af-E); (EA, Af, Af-EA, Af-EA-E) 6.2 
Others 37.5 
A4 
(EA, E, EA-E); (Af, Af-EA, Af-E, Af-EA-E) 29.4 
(EA); (E, EA-E); (Af, Af-EA, Af-E, Af-EA-A) 12.1 
(E), (EA, EA-E); (Af, Af-EA, Af-E, Af-EA-E) 6.3 
(Af, Af-EA, Af-E); (EA, E, EA-E, Af-EA-E) 6.2 
(EA, EA-E, Af-EA-E); (Af, E, Af-E, Af-EA-E) 5.9 
Others 40.1 
A2 
(EA, E, EA-E); (Af, Af-EA, Af-A, Af-EA-E) 32.1 
(EA); (E,EA-E); (Af, Af-EA, Af-E, Af-EA-E) 13.9 
(Af, Af-EA, Af-E); (EA, E, EA-E, Af-EA-E) 5.8 
(EA, EA-E, Af-EA); (Af, E, Af-E, Af-EA-E) 5.8 
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(E, EA-E, Af-E); (Af, EA, Af-EA, Af-EA-E) 5.7 
Others 36.7 
Table 12: Partitioning of ethnic groups in population genetics simulations. Extracted from 
Zakharov et al.155 
1 Populations in brackets define a single cluster; so, the notation (EA, E, EA-E); (Af, Af-EA, Af-E, 
Af-EA-E) means East Asian, European and the admixed East Asian-European populations were 
clustered together, whereas the rest of the populations formed another cluster. 











N12 0 12 (4A), (4A), (4A) 
N8 4 8 (4N), (4A), (4A) 
N4 8 4 (4N), (4N), (4A) 
N8C 4 8 (2A, 2N), (3A, 1N), (3A, 1N) 
N4C 8 4 (1A, 3N), (1A, 3N), (2A, 2N) 
A7 0 7 
P1: (3A), (4A) 
P2: (A), (2A), (4A) 
A4 3 4 
P1: (2A, 1N), (2A, 2N) 
P2: (1N), (2A), (2A, 2N) 
A2 5 2 
P1: (2A, 1N), (4N) 
P2: (1A), (1A, 1N), (4N) 
Table 13: Direct simulation from distributions of test statistics. Extracted from Zakharov et 
al.155 
1 Indicates the number and constituents of partitions observed from the population genetics 
simulations for the respective scenario, where the constituents refer to whether the study was 
under the null hypothesis (N) or under the alternative hypothesis (A). An example partition of (2A, 
2N), (3A, 1N), (3A, 1N) indicates that three clusters were observed, where the first cluster 
consisted of two studies under the alternative, and two studies under the null; the second and third 




Similar results were observed with the output from the burden analyses, with 
empirical false positive rates of 1.9 × 10-6 and 1.2 × 10-6 by Apcluster for the two 
corresponding classes, compared to those by the Fisher method (1.9 × 10-6, 1.3 × 
10-6) and the Stouffer method (1.6 × 10-6, 1.2 × 10-6). There was no significant 
elevation of false positives by these three approaches. We did not evaluate the 
empirical Type 1 error rates of Hom-Meta-SKAT, Het-Meta-SKAT and MV 
SKAT as the computation burden of these methods were extremely high for the 
number of simulations we performed, but evidence from the original publications 
of these methods indicated that these approaches are well-calibrated to control 


















12 3.0 × 10-7 5.0 × 10-7 1.9 × 10-6 1.6 × 10-6 4.5 × 10-7 1.9 × 10-6 
7 6.5 × 10-7 6.5 × 10-7 1.3 × 10-6 1.2 × 10-6 5.5 × 10-7 1.2 × 10-6 
Table 14: Empirical Type 1 error rates of p-value based meta-analysis methods at a 
significance threshold of p-value < 10-6. Extracted from Zakharov et al.155 
Power comparisons 
In evaluating the power of the different meta-analytic procedures, we chose 5% of 
the rare variants in each region to be functional and assigned the values of a 
quantitative trait as a function of the number of copies of the causal alleles 
carried. Power was then estimated as the proportion of the 1,000 simulations 
where the specific meta-analysis approach yielded statistical evidence of p-value 
< 10-6. We considered two classes of scenarios in the simulations involving 
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populations from three ancestry groups mimicking Africans, East Asians and 
Europeans. The first class assumes scenarios where studies originated from 
populations in these three ancestry groups without any admixture; while the 
second class assumes scenarios where studies originated from populations that are 
admixed between these three ancestry groups with different degrees of admixture.  
We observed that the burden tests yielded lower power in all the scenarios in our 
simulations when meta-analyzed with p-value-based methods (Figure 23). This 
was unsurprising as the burden test was expected to perform well when a high 
proportion of rare variants were associated with the outcome, whereas our 
simulations only assumed 5% of the rare variants to be causal. Our simulations 
assumed the presence of allelic heterogeneity across the different ancestry groups, 
which probably explained why MV SKAT and Hom-Meta-SKAT yielded 
consistently poorer performance than Het-Meta-SKAT. Intriguingly, we observed 
the Fisher method in combining the output from SKAT consistently outperformed 
Het-Meta-SKAT, a finding that contradicted the results of Lee et al87. This 
remained so even when we attempted to reproduce their findings by limiting the 
simulations to only three study groups under the alternative hypothesis for 3kb 
genomic region with rare variants defined as those with MAF  3% (Table 15, 
Figures 24-25), although we did replicate their finding that Hom-Meta-SKAT was 
superior to Fisher SKAT when we assumed allelic homogeneity between the 
populations.  
Our proposed approach with the output from SKAT (Apcluster SKAT) yielded 




Figure 23: Empirical power of different methods to perform meta-analysis. Extracted from 
Zakharov et al.155 
Empirical power to identify genomic regions simulated with 5% of the rare variants to be 
associated with a quantitative phenotype, as calculated from 1,000 iterations. We consider eight 
different scenarios corresponding to different degrees of allelic heterogeneity and admixture 
between populations from three ancestry groups between 12 studies (in scenarios N12, N8, N4, 
N8C and N4C) and 7 studies (in A7, A4 and A2). Two approaches (burden test, SKAT) were used 
to perform the association analysis within each study prior to meta-analyzing with Apcluster, the 
Fisher method or Stouffer inverse-normal method. We additionally included three recently 








Hetero E, A, Af None 
Homo E1, E2, E3 E1, E2, E3 
Mixed E1, E2, Af E1, E2 
Table 15: Population genetics simulation models for replication of findings of Lee et al. 
Extracted from Zakharov et al.155 
The simulations were conducted for 3kb regions with all ethnic groups being under the alternative 
hypothesis. Totally 5% of rare variants, defined as those with MAF≤3%, were chosen to be causal 
within each ethnic group. The phenotype model for each ethnic group is the same as described by 
the formula (1) with 𝑏𝑙 = 0.475| log10 𝑀𝐴𝐹𝑙 | as in Lee et al. The sample size for each ethnic 
group was 2400 individuals. The column “Populations under homogeneity” lists groups for which 






Figure 24: Empirical power of SKAT Fisher, Hom-Meta-SKAT and Het-Meta-SKAT on 
simulation scenarios for replication of results of Lee et al with MAF cutoff. Extracted from 
Zakharov et al.155 
Empirical power to identify genomic regions simulated with 5% of the rare variants (defined as 
those with 𝑀𝐴𝐹 ≤3% in haplotype pools) to be associated with a quantitative phenotype, as 
calculated from 1,000 iterations at the type-1 error rate of 2.5 × 10−6. We consider three different 
scenarios (denoted as “Hetero”, “Homo” and “Mixed”) corresponding to different degrees of 
allelic heterogeneity between three populations under the alternative hypothesis. Only variants 
with 𝑀𝐴𝐹 ≤3% in at least one population were included in analysis. For Hom-Meta-SKAT and 
Het-Meta-SKAT, if a variant was rare in one population but not rare (MAF > 3%) in another 
population group, we treated this variant as missing for all the study groups for which it was found 
to be not rare. For “Mixed” scenario grouping by ancestry was used in Hetero-Meta-SKAT, as in 





Figure 25: Empirical power of SKAT Fisher, Hom-Meta-SKAT and Het-Meta-SKAT on 
simulation scenarios for replication of results of Lee et al without MAF cutoff. Extracted 













Empirical power to identify genomic regions simulated with 5% of the rare variants (defined as 
those with 𝑀𝐴𝐹 ≤3% in haplotype pools) to be associated with a quantitative phenotype, as 
calculated from 1,000 iterations at the type-1 error rate of 2.5 × 10−6. We consider three different 
scenarios (denoted as “Hetero”, “Homo” and “Mixed”) corresponding to different degrees of 
allelic heterogeneity between three populations under the alternative hypothesis. All variants (both 
common and rare) were included in analysis. For “Mixed” scenario grouping by ancestry was used 
in Hetero-Meta-SKAT, as in Lee et al.  
 
were achieved in the N8, N4 and A2 scenarios with 3.2%, 6.4% and 3% increase 
in power compared to the next best method respectively. These three scenarios 
corresponded to the situations where there were greater degrees of heterogeneity 
between the 12 non-admixed and 7 admixed studies. To explore the origins of the 
power gain, we investigated the partitioning of the studies as derived by the 
affinity propagation clustering algorithm. We observed that in the non-admixed 
class, all 12 studies were always clustered into three partitions each containing 
four studies from an ancestry group. In the N8 scenario, this partitioning separated 
the four African studies under the null hypothesis from the other eight non-
African studies under the alternative hypothesis, and presented a meta-analysis 
framework with only six degrees of freedom compared to the traditional 24 
degrees of freedom.  
In addition, we have performed simulations for the non-admixed scenarios where 
we assumed allelic homogeneity for studies from the same ancestry, but allelic 
heterogeneity for studies from different ancestries. Specifically, the same causal 
variants were assumed for studies originating from populations in the same 
ancestry. Our results (Figure 26) indicated that while the methods that explicitly 
relied on allelic homogeneity (Hom-Meta-SKAT, MV SKAT) produced higher 
power in the N12, N8 and N4 scenarios than what was observed in the previous 
set of simulations, Apcluster always yielded comparable performance as these 
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methods. However, in scenarios which assumed heterogeneity in the effect sizes 
(N8C and N4C), the former two methods yielded significantly lower power than 
Apcluster.   
 
Figure 26: Empirical power of different methods to perform meta-analysis under 
homogeneity within each ancestry. Extracted from Zakharov et al.155 
Empirical power to identify genomic regions simulated with 5% of the rare variants to be 
associated with a quantitative phenotype, as calculated from 1,000 iterations. We consider five 
different scenarios corresponding to different degrees of allelic heterogeneity between populations 
from three ancestry groups between 12 studies. Allelic homogeneity was assumed for studies from 
the same ancestry, and allelic heterogeneity – for studies from different ancestries. Two 
approaches (burden test, SKAT) were used to perform the association analysis within each study 
prior to meta-analyzing with Apcluster, the Fisher method or Stouffer inverse-normal method. We 
additionally included three recently introduced methods: MV SKAT, Hom-Meta-SKAT and Het-
Meta-SKAT.  
Theoretical power simulations 
We simulated the test statistics directly from corresponding probability 
distributions under the null and alternative hypotheses according to the eight 
scenarios we have assumed in our population genetics simulations, and combined 
the p-values obtained from mapping the test statistics against a Chi-squared (1) 
distribution with the Fisher method and Apcluster. Overall, the trend in the power 
difference between the two approaches was independent of the non-centrality 








the size of . We observed that the Fisher method yielded marginally higher 
power for the N12, A7 and A4 scenarios, where the power difference was never 
more than 5% even at the most penalizing  (Figure 27 A, D, E). For scenarios 
N12 and A7, all of the test statistics were simulated under the alternative 
hypothesis, and thus the partitioning by Apcluster did not contribute any useful 
information to minimize heterogeneity in terms of association evidence. However, 
Apcluster yielded substantially higher power in scenarios N8, N4 and A2 (Figure 
27 B, C, F) with a potential power gain of 4.3, 16.7% and 13% in the N8, N4 and 
A2 scenarios respectively, since the partitioning by Apcluster separated the 
studies simulated under the null and alternative hypotheses. The powers of 
Apcluster and Fisher method were around the same when the partitioning was less 
informative, such as when each partition contained studies simulated under both 
the null and alternative hypotheses in the compound heterogeneity scenarios 
(N8C, N4C). The two most frequently observed partitionings of the seven studies 
(P1, P2) in the A2 model both yielded higher power than the Fisher method, since 
four out of the five studies under the null hypothesis were clustered together in 
both P1 and P2, thus significantly reducing the degrees of freedom for the test 
statistic under the null hypothesis.   
Discussion 
We have introduced a simple procedure for meta-analyzing genetic association 
studies of rare and low-frequency variants. Our approach partitions the studies 
into distinct clusters according to the extent of similarity surrounding the locality 




Figure 27: Power simulations from theoretical distributions. Extracted from Zakharov et 
al.155 
Under the alternative hypothesis, the test statistics of the association analysis follow a non-central 
Chi-squared distribution with a specific non-centrality parameter, while the p-value is calculated 
from a central Chi-squared (1) distribution. By sampling directly from the distributions under the 
null and alternative hypotheses, the power of Apcluster and the Fisher method for combining p-
values can be evaluated across different non-centrality parameters (horizontal axes) for the eight 
scenarios that corresponded to different degrees of allelic heterogeneity and admixture. Scenarios 
N8 and N8C are jointly represented in the same panel, as with scenarios N4 and N4C in a separate 
panel, since each of the two pairs corresponded to the same number of studies simulated under the 
null and alternative hypotheses respectively. For the admixed populations, the two most frequently 
observed partitionings (corresponding to P1 and P2) of the populations in the population genetics 
analyses were considered in the power simulations directly from the theoretical distributions. The 
range of non-centrality parameter for each scenario is chosen such that the power spectrum spans 
between 0% and 100%. 
 
based or region-based analysis of rare variants with the Fisher method. We show 
from our simulations that this additional step of partitioning increases the power 
to identify regions that contain variants that are genuinely associated with a 
phenotype, without elevating the false discovery rate. In addition, our method is 
robust to the presence of allelic heterogeneity across studies, especially when the 
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pattern of allelic heterogeneity correlates with background genomic 
heterogeneity.  
The intuition behind our method is straightforward: the meta-analysis of studies 
under the null hypothesis yields a measure of statistical evidence that is no 
different from a single study under the null hypothesis, but the conventional meta-
analysis wastes valuable degrees of freedom in accounting for the multiple 
studies; whereas the meta-analysis of studies under the alternative hypothesis 
yields substantially stronger evidence against the null hypothesis, and clustering 
only such studies for a joint analysis avoids attenuating the evidence that can be 
brought about when studies under the null are included. In designing our method 
to cluster the studies, we have leveraged on the principle that rare and low-
frequency functional variants have the tendency to segregate according to 
ancestry, and this appears to be a reasonable assumption in light of recent reports 
from whole-genome sequencing at the population level.157; 158 This is very much 
akin to the approach utilized in MANTRA that groups populations by FST.
159    
Our Apcluster approach provides a framework to perform the meta-analysis, 
although it relies on association evidence produced by methods such as SKAT or 
the burden test. The approach can naturally be applied to new methods for 
analyzing associations. The current setup assumes that study-level information 
such as the list of variants present within each study is available, in order to derive 
the extent of sharing between studies for every genomic locus to identify the 
partitions. In this manner, the partitionings obtained may differ according the 
region under consideration and in principle, provide a more informative manner to 
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represent the localized genetic diversity between the population groups. Sharing 
study-level information is straightforward since no individual-level information is 
exchanged. However, this is not strictly necessary and prior information on the 
degree of relatedness between study groups can be incorporated to cluster the 
studies.  
We emphasize that our method provides an additional scheme to discover 
phenotype associations, especially in light of the stringent criterion in defining 
genome-wide significance where including a few studies in a naïve meta-analysis 
can attenuate the overall signal below the threshold of significance. Findings that 
emerge from this scheme need to be subject to the same scrutiny and need for 
further validation just as regions that emerge from the conventional Fisher method 
or other more sophisticated approaches. The partitioning of the studies may guide 
the selection of the populations to perform the replication experiment in, since 
there may be natural population or ancestry clades that are carrying the 
association signals. At the very least, it can help to put in perspective the failure to 
reproduce a finding, if validation was carried out in populations that coincided 
with those studies in a cluster that yielded evidence in favor of the null 
hypothesis.  
Conclusions 
We have described a novel methodology that addresses the unique challenges of 
trans-ethnic rare variants meta-analysis. Population genetics simulations and 
theoretical power simulations showcased the advantages of the proposed approach 
over existing conventional and recent methods.  
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Chapter 6 – Conclusion 
Discoveries of novel regions harboring associated rare variants with large effects 
improve our understanding of complex diseases and, as a result, are likely to 
contribute significantly towards the development of effective treatment strategies. 
However, finding truly associated rare variants poses significant challenges, 
particularly in the area of methodology of statistical analysis.   
This thesis focused on addressing some of the issues in the field of statistical 
genetics of rare variants. Specifically, the aims of the thesis were: (i) to provide a 
performance comparison of similarity-based tests on rare variants association 
scenarios; (ii) to develop a powerful region-based rare variants statistical test that 
incorporates prior information; (iii) to describe a statistical strategy that possesses 
high performance on both genotype- and haplotype-based association scenarios; 
(iv) to develop a powerful trans-ethnic region-based rare variants meta-analysis 
method. As a result, we have performed one comparison of statistical tests and 
have developed three novel methodologies for the region-based rare variants 
analysis. The comparison of similarity-based tests revealed that when the 
association signal was born by rare variants weighting was a better strategy to 
accommodate rare variants within a test. This is likely to be due to the emphasis 
of weighting on variants with lower minor allele frequencies. However, when the 
association signal was born by common variants, collapsing was a better strategy. 
This result may be explained by the reduction of the number of variable for an 
association analysis. Also, the comparison showed that SKAT and KBAT test had 
consistently higher power compared with other considered similarity-based tests 
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when applied with the appropriate rare variants pooling strategy. Our novel rare 
variant method that incorporates prior information may be a powerful strategy 
because partitioning of variants using prior information may effectively separate 
associated variants from neutral ones. Our MinP-val method preserves high power 
for both genotype- and haplotype-based scenarios due to its robust combination of 
haplotype and genotype-based methods into a single statistical test. Finally, our 
Apcluster trans-ethnic rare variants meta-analysis method is a powerful strategy in 
the case when partitioning of ethnic groups using a population genetics argument 
minimizes the effect size heterogeneity within clusters, which facilitates both the 
reduction of degrees of freedom from neutral ethnic groups and strengthening of 
evidence against the null hypothesis when multiple strongly associated ethnic 
groups are within one cluster.  
These results are a part of research directed towards a broader purpose of finding 
the most optimal strategies for statistical analysis of rare variants in association 
studies. Although finding a single most optimal method is unlikely, we can keep 
developing novel methods and evaluating their performance to be aware of 
advantages and drawbacks of each method.  This will help researchers to make an 
informed decision when choosing a statistical method for their analysis. The 
results of this thesis bring us closer to achieving the broad purpose by providing 
novel powerful methodologies for rare variants analysis, which in future could 
help researcher discover novel associations of rare variants with diseases and 
traits. Also, both the investigation of performance of novel methods relatively to 
the proposed ones and the comparison of similarity-based tests help to discover 
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the most robust and powerful methods across different association scenarios, 
which is useful for choosing the right statistical tools for rare variants analysis. It 
should be emphasized that Study 4, which presents a novel trans-ethnic rare 
variants meta-analysis method, is likely to be the most significant contribution of 
the thesis since meta-analysis of multiple studies across populations may be the 
best approach for identification of associated rare variants due to a significant 
increase of sample size relatively to each individual study. 
This thesis has concentrated on statistical approaches for association studies of 
unrelated individuals with dichotomous or quantitative trait since this type of 
association studies is one of the most commonly done in practice. Also, we have 
not considered Bayesian approaches, which have a very different rationale for 
quantifying evidence against the null hypothesis of no association. Finally, it 
should be noted that in all the studies we have applied simulations to evaluate the 
performance of the methods. Those simulations are based on the assumptions 
concerning the underlying disease model, such as the magnitude and distribution 
of effect sizes, proportion and choice of causal variants etc. Although we have 
chosen our assumptions carefully to be consistent with the current empirical 
findings, disease models in reality are much more complex and diverse. Thus, the 
performance of the methods on simulations should be considered as a rough 
approximation to the expected performance in the real association studies. 
The future research may be directed towards addressing other issues within the 
field of statistical genetics. For example, a limited research has been done to 
develop powerful pathway-based rare variants methods. As causal rare variants 
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may be spread within a set of biologically connected genes, it is important to 
develop powerful methodologies of rare variants analysis within pathways. 
Definitely, one may treat a pathway as an extended region and thus apply any 
available region-based method to the whole pathway; however, it is unclear if this 
is the best approach. Another area for future research may be the joint analysis of 
family and unrelated samples data in association studies of rare variants. Since 
both types of data may be available for a genomic region, it is of interest to 
develop powerful methodologies for the joint analysis. As noted above, the 
ultimate aim of statistical genetics of rare variants is to identify the most optimal 
methodologies for sequencing association studies. Thus, much further research 
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Appendix to Chapter 1 
Statistical test 
If known how to 
adjust for covariates 









   
CAST25 Yes Yes Yes 
Zawistowski et al26 Categorical only No Yes 
CMC28 Yes Yes Yes 
Weighted Sum29 Yes Yes Yes 
Methods that account for heterogeneous trait effect 
Lin and Tang30 No No No 
Zhang et al31 No No No 
Sha et al32 No No No 
Han and Pan33 No No No 
Dai et al34 No No No 
C-alpha35 No Yes No 
Ionita-Laza36 No No No 
Truncated product of p-
values37 
No No No 




SSU test39 Yes No No 
Similarity-based tests 
U-test44 No No Yes 
KBAT46 No No No 
Mantel test47 No No No 
MDMR48 No No No 
SKAT41 Yes Yes No 
SKAT - O51 Yes Yes No 
Methods based on variable selection 
Penalized regression Yes Yes No 
Variable threshold56 No No Yes 
Fang et al57 No No Yes 
Bhatia et al58 No No Yes 
Ionita-Laza et al59 No No Yes 
Tests that incorporate prior information 
Asimit et al65 No No No 
Moore et al66 Yes Yes Yes 
King et al67 Yes Yes No 
Rare haplotype tests 
Weighted haplotype 
method74 
No No No 










No Yes No 
Wang et al78 Yes No No 
KBAC79 Yes Monte-Carlo Yes 
Private variants test22 No Exact Yes 
RWAS80 No No Yes 
Spatial approach81 No No No 
Table 16: Summary of region-based rare variants statistical methods. 
Appendix to Chapter 2 
Let us follow the notations adopted in Chapter 2. For simplicity assume equal 
number of cases and controls. Given that 𝑡𝑟(𝐴𝐵) = 𝑡𝑟(𝐵𝐴) for any real matrices 
















Since 𝐺 = (𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁)𝐴(𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁) we can rewrite: 





𝑇 /𝑁)𝐻(𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁))
𝑡𝑟 (𝐴 (𝐼𝑁 −
1𝑁1𝑁
𝑇
𝑁 ) (𝐼𝑁 −
1𝑁1𝑁
𝑇
𝑁 )) − 𝑡𝑟(𝐴
(𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁)𝐻(𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁))
. 
Given the matrix (𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁) is idempotent and (𝐼𝑁 − 1𝑁1𝑁
𝑇 /𝑁)𝐻(𝐼𝑁 −
1𝑁1𝑁
𝑇 /𝑁) = 𝐻 when number of cases and controls are equal (as 1𝑁
𝑇 𝑌 = 𝑌𝑇1𝑁 =
0) it follows: 
𝑀𝐷𝑀𝑅 =
𝑡𝑟(𝐴𝐻)
𝑡𝑟(𝐴) − 𝑡𝑟 (
𝐴1𝑁1𝑁
𝑇
𝑁 ) − 𝑡𝑟(𝐴𝐻)
. 
(37) 
If we assume exponential similarity measure, the diagonal of similarity matrix 𝐾 
is 1, so the diagonal of dissimilarity matrix 𝐷 as far as those of matrix 𝐴 is zero; 
thus, 𝑡𝑟(𝐴) = 0. Next, 𝑡𝑟(𝐴𝐻) = 𝑡𝑟 (
𝐴𝑌𝑌𝑇
𝑁








𝑇 (−2𝐴)1𝑁 − 𝑌𝑇(−2𝐴)𝑌
, (38) 










corresponding to all case-case, control-control and case-control 
pairs (a pair (𝑖, 𝑗) is different from (𝑗, 𝑖)). So, we can rewrite the test statistic as: 
𝑀𝐷𝑀𝑅 =
𝐷11 + 𝐷00 − 𝐷10
−(𝐷11 + 𝐷00 + 𝐷10) − (𝐷11 + 𝐷00 − 𝐷10)
=


















where 𝐶 = 𝐷10 + 𝐷11 + 𝐷00 is constant when permutation test is applied. Given 
that 0 < 𝐷10 < 𝐶 and the function 𝑓(𝑥) = −0.5 + 𝑥/(2𝐶 − 2𝑥) is strictly and 
monotonically increasing for 0 < 𝑥 < 𝐶, the 𝑀𝐷𝑀𝑅 test statistic is equivalent to 
𝐷10. From the definition of matrix 𝐷: 






For the purpose of comparison let us transform the 𝑆𝐾𝐴𝑇 test statistic. Taking 
into account the different phenotype coding for SKAT test: 
























where 𝐶′is the sum of all elements in the similarity matrix. Note, 𝐶′ is constant for 
permutation test. It is easy to show that the 𝑆𝐾𝐴𝑇 test statistic is equivalent to: 





As can be seen, 𝑆𝐾𝐴𝑇 and 𝑀𝐷𝑀𝑅 test statistics are equivalent to a sum of and a 
sum of squares of dissimilarities for all case-control pairs respectively.  
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Appendix to Chapter 3 
Link between non-centrality parameter and effect size for the region-based 
score test 
Adopting the notations from Chapter 3, let us consider the element of the score 
vector 𝑈𝑙 = ∑ (𝑦𝑛 − ?̅?)(𝑔𝑛𝑙 − 𝑔?̅?)
𝑁
𝑛=1
, 𝑙 = 1, … , 𝐿. Denote the number of cases, 
controls and total sample size as 𝑁𝐴, 𝑁𝑈 and 𝑁 = 𝑁𝐴 + 𝑁𝑈. After algebraic 









− are the observed MAF in cases and controls, respectively, for 
the 𝑙th SNP. Then, the vector 𝑆 = 𝐶𝑈 is asymptotically distributed as a 
multivariate random vector with the unit covariance matrix and mean 𝐶𝐸(𝑈), 
where 𝐸(𝑈) is the mathematical expectation of the score vector, which can be 
written as follows: 
𝐸(𝑈) = 𝐸({𝑈𝑙}𝑙=1
𝐿 ) = {2𝑁𝐴𝑁𝑈(𝑒𝑓𝑙
+ − 𝑒𝑓𝑙
−)/𝑁}𝑙=1
𝐿 , (44) 
where 𝑒𝑓𝑙
+ and 𝑒𝑓𝑙
− are population MAF in cases and controls of the 𝑙th variant. 
If we denote as 𝑅𝑙 relative risk of the 𝑙th SNP and assume low prevalence of a 










The score test statistic is the sum of squares of elements of vector 𝑆. If we define 
vector 𝜉 = {𝜉𝑙}𝑙=1
𝐿 = 𝐸(𝑆) = 𝐶𝐸(𝑈), then the non-centrality parameter (NCP) of 
the score test statistic under the alternative hypothesis is:  





Under the null hypothesis of no variant being associated with a phenotype, which 
is equivalent to 𝑅𝑙 = 1, 𝑙 = 1, … , 𝐿, it follows from (45) that 𝑒𝑓𝑙
+ = 𝑒𝑓𝑙
−, which 
implies from (44) 𝐸(𝑈𝑙) = 0, 𝑙 = 1, … , 𝐿 and 𝜉 = 𝐶𝐸(𝑈) = {0}𝑙=1
𝐿 ; thus, 𝑟 = 0. 
Illustration of connection between non-centrality parameter and effect size  
From the considerations above, it can be seen that NCP 𝑟 is a function of the 
number of cases 𝑁𝐴 and controls 𝑁𝑈in the study, relative risk of each variant 
𝑅𝑙 , 𝑙 = 1, … , 𝐿; population MAF in controls 𝑒𝑓𝑙
−, 𝑙 = 1, … , 𝐿; and covariance 
matrix of the score test statistic 𝑉 (since matrix 𝐶 = (𝐴𝑇)−1, where 𝑉 = 𝐴𝑇𝐴).  
To illustrate the dependence between NCP and relative risk let us assume 
independence of variants within the region, which implies the matrix 𝑉 is 
diagonal. Thus, 𝑉 = 𝑑𝑖𝑎𝑔({𝑣𝑙}𝑙=1
𝐿 ) where 𝑣𝑙 = 𝑣𝑎𝑟(𝑔𝑙) is variance of the 𝑙th 






+, which is variance of the sum of two independent binomial 
random variables with the number of draws 2𝑁𝑈 and 2𝑁𝐴 and the probability of 
success 𝑒𝑓𝑙
− and 𝑒𝑓𝑙





Figure 28: The non-centrality parameter (vertical axis) as a function of the effect size 
(relative risk) of each causal variant (horizontal axis) under the assumptions described in 
Appendix. Adapted from Zakharov et al.114 
Curves within each panel correspond to the number of causal variants within the region. The 
assumptions are as follows: all variants within a region are independent; all the causal variants 
have the same MAF and the same effect size; 500 cases and 500 controls. The MAF of the causal 
variants are as follows: Panel 1 – 1%; Panel 2 – 0.5%; Panel 3 – 0.25%: Panel 4 – 0.125%. 
 
𝐶 = 𝑑𝑖𝑎𝑔(1/√2𝑁𝐴(1 − 𝑒𝑓𝑙
+)𝑒𝑓𝑙
+ + 2𝑁𝑈(1 − 𝑒𝑓𝑙
−)𝑒𝑓𝑙
−  , 𝑙 = 1, … , 𝐿). (47) 
So, given population MAF of causal variants in controls 𝑒𝑓𝑙
−, relative risk of 
causal variants 𝑅𝑙, the number of cases 𝑁
𝐴 and controls 𝑁𝑈, we can calculate the 




+ – population MAF in cases from (45); 
2. calculate 𝐸(𝑈) – the expectation of the score vector 𝑈 from (44); 
3. obtain matrix 𝐶 from (47); 
4. calculate vector 𝜉 = {𝜉𝑙}𝑙=1
𝐿 = 𝐶𝐸(𝑈); 
5. obtain NCP 𝑟 from (46). 
For the purpose of illustration, let us assume 𝑁𝐴 = 𝑁𝑈 = 500, population MAF 
and relative risk of all causal variants are equal. Figure 28 depicts the non-
centrality parameter (vertical axis) as a function of relative risk (horizontal axis) 
and the number of causal variants (lines within each panel). Population MAF of 
causal variants in controls was the following: Panel 1 – 1%, Panel 2 – 0.5%, Panel 
3 – 0.25%, Panel 4 – 0.125%. As can be seen, the non-centrality parameter 
monotonically increases with increasing relative risk, population MAF in controls 
and the number of causal variants within a region. 
Appendix to Chapter 4 
Results of additional simulation analysis 
We investigated the performance of the proposed strategies for a different pair of 
underlying tests. For a genotype-based test we used a Gene Score test described in 
Zhao and Thalamuthu160 with Madsen-Browning weights29 calculated across all 
the samples. Briefly, for a 𝑛 × 𝐿 genotype matrix 𝐺 (SNPs in columns), vector of 
weights 𝑤 = (𝑤1, … , 𝑤𝐿) and 𝑛 × 1 vector 𝑌 of dichotomous phenotype, the 
logistic model 𝑙𝑜𝑔𝑖𝑡(𝑌) = 𝑎 + (𝐺𝑤)𝑏 is considered. The genotype Gene Score 
test is a t-test of 𝑏 coefficient for the null hypothesis 𝐻0: 𝑏 = 0. Haplotype Gene 
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Score test is a t-test of the respective coefficient in a logistic regression of 
phenotype against the haplotype score. The haplotype score of an “individual” is 
the sum of Madsen-Browning weights (calculated from haplotype frequencies 
across all the samples) corresponding to the two haplotypes. 
Panel 4 of Figure 29 shows the empirical type-1 error estimate for the theoretical 
level of 0.05 for all the tests. As can be seen, in our simulations the type-1 error 
was well controlled for all the tests. Panels 1-3 of Figure 29 depict the results of 
population genetics simulations analysis for all the phenotype models with 50%, 
20% and 10% of rare causal variants/haplotypes, respectively, at the fixed 5% 
type-1 error rate. Haplotypes were assumed to be known without ambiguity. We 
also performed the same analysis with haplotypes inferred with Beagle using the 
reference panel of 1094 individuals to mimic the size of the publicly available 
reference panel from the 1000 Genomes Project (www.1000genomes.org) —and 
the results were very similar (data not shown). As can be seen from Figure 29 for 
genotype scenarios genotype Gene Score test performed better or equally good 
compared with haplotype Gene Score test, whereas for haplotype risk scenarios 
the result was the opposite, except for the “Common” model. This may be 
explained by the fact that the frequency of some common haplotypes may be very 
high (for example, wild type haplotype); so, if a very common haplotype is 
chosen to confer risk, it will be underweighted too much in haplotype Gene Score 
test. Since both Gene Score tests were designed to account for the potential effect 
of rare variants or rare haplotype, the relative power of the tests under common 
disease scenarios may not follow the expectations. It is also notable that MinP-val 
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test was on par with SumP-val method for all the phenotype models, except when 
one of the underlying tests significantly underperformed the other underlying test. 
In these cases, MinP-val performed better than SumP-val, which is consistent 
with the conclusions obtained previously. 
Results of additional analysis of central corneal thickness GWAS data set  
In addition to the main genome-wide analysis of the SiMES+SINDI data set, we 
applied our proposed methods with different pair of underlying tests to the three 
regions reported by Vithana et al.135 For the genotype-based test we utilized the 
regression on principal component (PC) scores.128 To describe the methodology, 
let us denote 𝐺 as 𝑛 × 𝐿 genotype matrix, where 𝑛 is the sample size and 𝐿 is the 
number of SNPs within a region, 𝑌 is 𝑛 × 1 vector of quantitative phenotype, 𝐶 is 
𝑛 × 12 matrix of covariates which include age, gender and the first ten genotype 
principal components obtained from Eigenstrat.49 Further, let us define the 𝑛 × 𝑝 
matrix 𝑃 whose columns are principal component scores obtained from 𝐺. The 
matrix 𝑃 contains the minimum number of principal components with the 
cumulative variance no less than 80% of the total variance.128 In other words, the 
principal components in order from highest to lowest variance were recursively 
added to the matrix 𝑃 until the sum of variances of the columns exceeded 80% of 
the total variance (sum of variances of all principal components). This procedure 
reduces the number of variables while preserving the major share of genotype 
variability. Further, the following regression model 𝑌 = 𝑎 + 𝑃𝑏1 + 𝐶𝑐 + 𝜀 was 











Figure 29: Power comparison of the gene score haplotype test, the gene score genotype test, 
MinP-val and SumP-val statistical tests for population genetics simulations, and an estimate 
of empirical type-1 error. Extracted from Zakharov et al.134 
In each panel the top three disease models correspond to the haplotype-based disease scenario, 
whereas the lower three correspond to the genotype-based scenario. Disease models “Rare”, 
“Both” and “Common” are described in the section “Population genetics simulation”. Type-1 error 
is set to 5%. Panel 1: 50% of rare variants/haplotypes were assumed to be causal; Panel 2:  20% of 
rare variants/haplotypes were assumed to be causal; Panel 3:  10% of rare variants/haplotypes 
were assumed to be causal; Panel 4:  empirical type-1 error estimate for simulations under the null 
hypothesis. 
 
regression coefficients, and 𝜀 is 𝑛 × 1 vector of error terms. A statistic to test the 




𝑆𝑆𝐹/(𝑛 − 𝑝 − 13)
, (48) 
 
where 𝑆𝑆𝐹 is the sum of squared residuals, and 𝑆𝑆𝑅 is the sum of squared 
residuals in the reduced model 𝑌 = 𝑎 + 𝐶𝑐 + 𝜀. Under the null hypothesis the test 
statistic 𝐹1 is asymptotically distributed as F random variable with 𝑝 and 𝑛 − 𝑝 −
13 degrees of freedom, since CCT phenotype is a normally distributed trait.135 For 
the haplotype-based test we applied the regression on haplotype clusters obtained 
from the affinity propagation clustering algorithm.130 Clustering of haplotypes is 
needed to reduce the degrees of freedom of F-statistic and to overcome the 
difficulty of analyzing rare haplotypes within a regression framework. Affinity 
propagation is a clustering algorithm built on the idea of exchanging real-valued 
messages between data points until “a high quality set of exemplars and 
corresponding clusters gradually emerge”.153 The input of the algorithm requires a 
similarity matrix {𝑠(𝑖, 𝑗)}𝑖,𝑗=1
𝑁 , where, for 𝑖 ≠ 𝑗 the element 𝑠(𝑖, 𝑗) is a measure of 
how well the data point 𝑗 is suited to be an exemplar for the data point 𝑖, and for 
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𝑖 = 𝑗 the element 𝑠(𝑖, 𝑖) is a measure of likelihood of the data point 𝑖 to be an 
exemplar (cluster center). Let us assume we have ℎ unique haplotypes {𝐻𝑘, 𝑘 =
1, … , ℎ} for a region (a haplotype 𝐻𝑘 can be written as a vector 
{𝑥𝑘1, 𝑥𝑘2, … , 𝑥𝑘𝐿}, 𝑥𝑘𝑙 ∈ {0,1}). The order of markers on a haplotype is assumed to 
be the physical order on the chromosome. To construct ℎ × ℎ haplotype similarity 
matrix 𝑠(𝑖, 𝑗) Jin et al130 utilized the following measure: 









, 𝑖 ≠ 𝑗 (49) 
where 𝑝(𝑥𝑖𝑙) = 𝑃(𝑥𝑖𝑙|𝑥𝑖𝑙−1) is the likelihood of the observed allele on the 
haplotype 𝐻𝑖 on the place 𝑙 conditional upon the observation of an allele on the 
place 𝑙 − 1 (this model corresponds to the first-order Markov chain model 
suggested by Jin et al130). These probabilities are estimated using the inferred 
haplotypes across all individuals. The elements 𝑠(𝑖, 𝑖) are equal to the median of 
values 𝑠(𝑖, 𝑗), 𝑖 ≠ 𝑗, which corresponds to the default setting of the ‘apcluster’ 
function in the affinity propagation R (www.r-project.org/) package “apcluster”. 
For COL8A2 gene we forced the algorithm to output two clusters as the initial run 
gave only one haplotype cluster. Next, let us assume that all the ℎ haplotypes are 
split into 𝑘 clusters 𝑆1, … , 𝑆𝑘, where we let the cluster 𝑆𝑘 to be the most frequent 
(assigned to be the reference cluster). The 𝑛 × (𝑘 − 1) regression matrix 𝑅 =
{𝑅𝑖𝑗}𝑖=1,𝑗=1
𝑛,𝑘−1
 is constructed as follows: value of 𝑅𝑖𝑗 is the number of haplotypes of 
𝑖th individual that belong to cluster 𝑆𝑗. After the construction of 𝑅 matrix the 
regression model is considered: 𝑌 = 𝑎 + 𝑅𝑏2 + 𝐶𝑐 + 𝜀, where 𝑏2 is (𝑘 − 1) × 1 
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vector of regression coefficients. The test statistic 𝐹2 for the null hypothesis 
𝐻0: 𝑏2 = 0 is analogous to 𝐹1. The asymptotic distribution of 𝐹2 is F-distribution 
with 𝑘 − 1 and 𝑛 − (𝑘 − 1) − 13 degrees of freedom. Permutations of residuals 
under the reduced model were applied to estimate the correlation 𝜌 between the 
inverse standard normal transforms of theoretical p-values of the underlying tests. 
To justify our assumption of bivariate normality we applied the Shapiro-Wilk test. 
The corresponding p-values for the three regions are presented in Table 17. All p-
values were non-significant at 5% type-1 error rate which suggests there was no 
evidence against the assumption of bivariate normality. Table 18 shows 
theoretical p-values for the described genotype and haplotype tests, and for MinP-
val and SumP-val approaches. As can be seen, in spite of haplotype-based test 
yielding high p-values, both of the proposed methods performed on par with the 
genotype-based test. It is notable that single-SNP p-values reported by Vithana et 
al135 were more significant than all the other tests considered. However, for the 
region-based analysis the genome-wide significance level was 1.38E-6 (this 
corresponds to 36146 genes and between-gene blocks), which implies the results 






test 0.49 0.77 0.63 
Table 17: Additional real data analysis: p-values for the Shapiro-Wilk test. Extracted from 











2.4E-12 3.7E-12 1.2E-08 
Haplotype test p-
value 
0.9 9.3E-06 4E-05 
MinP-val 4.9E-12 7.30E-12 2.5E-08 
SumP-val 1.6E-11 4.52E-12 2.3E-09 
Single-SNP analysis 









Table 18: Additional real data analysis: the results of the real data analysis and the single-
SNP p-values (SiMES and SINDI meta-analysis) from the original article. Extracted from 
Zakharov et al.134 
Genome-wide significant p-values for gene-based tests are shown underlined. 
